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Abstract 
Autosomal recessive congenital ichthyosis (ARCI) is a rare cornification disorder with 
impaired skin barrier function and with no causative treatment available. Eleven genes are 
involved in different ARCI phenotypes, all related to epidermal differentiation. Mutation in 
TGM1 is the main cause of ARCI, and it encodes for the enzyme transglutaminase 1 (TGase1), 
which is involved in the keratinocyte differentiation and in the formation of the cornified cell 
envelope. Mutations in TGM1 cause lamellar ichthyosis and congenital ichthyosiform 
erythroderma phenotypes, causing also self-healing collodion babies. 
In this project, we aimed to study the fate of the protein-loaded thermoresponsive PNIPAM-
dPG nanogel for cutaneous protein TGase1 delivery for restoring the skin barrier function in 
ARCI patients with TGM1 mutation.  
To accomplish this, TGase1 delivery was analysed in keratinocytes grown in a 2D monolayer 
and in 3D skin models. We first studied the gene expression of TGM1 and other specific 
markers for ARCI on RNA level. As TGM1 was expressed in all our cell models (human 
control, human ARCI-patient with TGM1 mutation, and pig control keratinocytes), we 
subsequently developed three-dimensional skin models to evaluate the destiny of the 
TGase1/NG complex in the skin. Observing the successful delivery of TGase1 and nanogel in 
the epidermis, we carried out the study of their location in keratinocytes in a 2D monolayer. 
Our findings suggested that TGase1 and nanogel enter the keratinocytes, release one from each 
other, and they are located around the nuclei, in the cytoplasm and in the plasma membrane. 
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1. INTRODUCTION 
1.1. SKIN: STRUCTURE AND BARRIER FUNCTION 
1.1.1. HUMAN SKIN 
Skin is the largest and one of our body’s heaviest organ. Skin is the primary protective organ 
of the human body, with a measure about 1.5-2 m2 in adults, covers the body’s entire external 
surface and serves as a first-order physical barrier against the environment (Richardson, 2003; 
Lai-Cheong and McGrath, 2017; Lopez-Ojeda and James, 2017). The skin permeability barrier 
is located in the horny layer of the epidermis and serves a vital function by protecting against 
water loss from the body. It prevents the invasion of pathogens, allergens, UV light and 
chemicals, takes part in metabolic processes, and plays a thermoregulatory function. Barrier 
dysfunction can be involved in the pathophysiology of cutaneous disorders, for example, 
ichthyosis; infectious diseases, and dry skin, as this can be caused by certain mutations that can 
lead to an impairment of skin barrier formation (Landmann, 1988; Kolarsick, Kolarsick, and 
Goodwin, 2011; Boer et al., 2016; Kihara, 2016). 
Looking at its structure, skin consists of three layers: the outer epidermis (a superficial 
epidermal layer), the inner dermis (a deeper, thicker dermal layer), and subcutaneous tissue 
that links the upper layers to the adjacent tissues and organs (Lai-Cheong and McGrath, 2009; 
Kolarsick, Kolarsick, and Goodwin, 2011; Eckl et al., 2013). 
Each of these layers contains different cell types and is involved in specific functions (Figure 
1). The epidermis is mainly formed by keratinocytes (95% of cells), that synthesize major 
structural elements of the epidermal barrier and catalytic proteins during a programmed process 
of differentiation. Keratins, filaggrin, involucrin and transglutaminases are these synthesized 
compounds. Keratinocyte differentiation is enhanced by calcium, hydrocortisone, and vitamin 
A depletion, and is usually suppressed by retinoids and low calcium levels. Keratinocytes form 
the outer skin layer and are therefore important in epidermal renewal as they participate in 
skin’s immune defence, constituting the first line of defence against percutaneous pathogens. 
Melanocytes, Langerhans cells and Merkel cells constitute the remaining 5% of the cells. 
Melanocytes are cells originated from the neural crest that are important in skin’s pigmentary 
system as they produce melanin. These cells can also secrete signalling molecules. They can 
be found at many locations in the body; specifically, in the skin, they are associated with the 
hair follicle, and in some mammals like humans, melanocytes are also found in the basal layer 
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of the interfollicular epidermis. Mature melanocytes make contact with around 30-40 
keratinocytes forming the epidermal-melanin unit. In this way, melanocytes transfer melanin 
into keratinocytes, determining the skin colour. This also helps to protect against the damaging 
effects of ultraviolet radiation (UVR). Langerhans cells (LC), the skin epidermal contingent of 
dendritic cells (DC), constitute a group of mononuclear phagocytes that are seeded from 
macrophage precursors in the skin epidermis before birth. LC are cells that play an important 
role in local defence mechanisms and are thought to act as antigen-presenting cells.  Merkel 
cells are located in the basal layer of the epidermis at certain different areas of hairy skin in 
mammals. They are cells with many features, such as neuroendocrine and epithelial 
characteristics that synapse with the dermal sensory axons and adjacent epithelial cells and are 
sensitive to mechanical stimuli. Merkel cells therefore act as an adapting mechanoreceptor 
through their Merkel nerve endings. Furthermore, those cells that are not associated to nerve, 
may participate in endocrine or paracrine secretion (Eckert and Rorke, 1989; Tsatmali, Ancans, 
and Thody, 2002; Fradette et al., 2003; Moll et al., 2005; Fore, 2006; Lai-Cheong and McGrath, 
2009; Suter et al., 2009; Jaitley and Saraswathi, 2012; Cichorek et al., 2013; Arda, Göksügür, 
and Tüzün, 2014; Min et al., 2017; West and Bennett, 2018). 
The dermis is 0.55 mm thick, depending on body site, and is embryologically originated from 
the mesoderm. It contains interstitial (collagen fibres, elastic tissue) and cellular (such as 
fibroblasts, plasma cell or histiocytes) components. It is also composed of lymphatic channels, 
blood vessels and sensory nerves (Lai-Cheong and McGrath, 2009; Krieg and Aumailley, 
2011; Tracy, Minasian, and Caterson, 2016; Lopez-Ojeda and James, 2017). Collagen is the 
major stress-resistant material of skin and is a fibrous family constituted of at least 15 different 
types in human skin.  Collagen types I and III are the prominent fibrillary protein in the human 
dermis, becoming about 70% of its dry weight. Elastic fibres account for about 5% and consist 
of elastin and elastic microfibrils, maintaining elasticity (Meigel, Gay, and Wever, 1977; Gelse, 
Pöschl, and Aigner, 2003; Lai-Cheong and McGrath, 2009; Kolarsick, Kolarsick, and 
Goodwin, 2011). Fibroblasts are a heterogeneous and dynamic cell lineage that can be found 
in most tissues in the body. They play a key role in normal wound healing, as they produce big 
amounts of collagenous matrix helping to isolate and repair the damaged tissue. Apart from its 
importance in wound healing, they also regulate extracellular matrices, interstitial fluid volume 
and pressure. Their survival, metabolism and migration are influenced by the action of 
extracellular matrix components. They have also the ability of differentiating into other 
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members of the family (Alberts et al., 2002; McAnulty, 2007; Tracy, Minasian, and Caterson, 
2016).  
The subcutaneous layer or hypodermis is mainly formed by fat and connective tissue, and it is 
the deepest layer of the skin (Ahn and Kaptchuck, 2011; Yousef and Sharma, 2017).  
 
Figure 1. Schematic representation of normal skin structure. Different layers of the skin 
and their components (from National Cancer Institute at the National Institute of Health). 
 
Mammalian epidermis is composed of four layers, or “strata": stratum basale, stratum 
spinosum, stratum granulosum and stratum corneum. The inner layer, called basal layer, is a 
germinal epithelium that produce all the cells of the epidermis. It is separated from dermis by 
basal lamina or basement membrane (a specialized extracellular matrix structure) and attached 
by hemidesmosomes and integrin-based adhesions. The keratinocytes proliferate in this layer 
and migrate outward while differentiating into cell layer-specific cells. Melanocytes can be 
identified in the stratum basale. While basal cells of the basal layer stay attached to an 
underlying matrix and proliferate, some of their daughter keratinocytes go to the stratum 
spinosum. The spinous layer is the layer next to the stratum basale and the basal cells move 
towards the surface producing a layer of polyhedral cells connected by desmosomes. 
Langerhans cells also sit within this layer. Keratinocytes in the stratum granulosum contain 
intracellular keratohyalin granules where profilaggrin, the precursor of filaggrin, is integrated. 
Cells get together a water-impermeable cornified envelope carrying the plasma membrane. The 
lipids are secreted by the cells into the intercellular space, being important for the barrier 
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function and intercellular cohesion within the stratum corneum (or horny layer). The stratum 
corneum is the outermost layer of the epidermis, is where the skin barrier is fundamentally 
formed, and forms a continuous sheet of protein-enriched cells (corneocytes) connected by 
corneodesmosomes and embedded in an intercellular matrix. The corneocytes are the migrated 
cells from the granular cell layer that have lost their nuclei and cytoplasmic organelles. It takes 
about 28 days, in healthy skin, for a basal keratinocyte to move through all the layers and 
differentiate to a corneocyte (Gilbert, 2000; Richard, 2004; Proksch et al., 2008; Venus, 
Waterman, and McNab, 2010; Eckl et al., 2013; Kihara, 2016; Yousef and Sharma, 2017). 
Embryonic epidermis starts as a monolayer of ectodermal cells that will form a multilayered 
epithelium by stratification and in response to particular transcription factors. Once built, the 
epidermis is maintained by frequent stratification and differentiation of keratinocytes in adult 
life. Epidermal differentiation begins with the migration of keratinocytes from the basal layer 
and ends with the formation of the cornified layer at the late stages of keratinocyte 
differentiation (Figure 2). The cells become more permeable to calcium and other ions when 
they migrate into the upper skin layer. Calcium influence activates a keratinocyte-specific 
transglutaminase that catalyzes the formation of the cornified envelope (CE). CE serves a 
barrier function for the organism, helping to keep the structural integrity of the epidermis. The 
cornified layer is in the upper layer of epidermis and is composed of terminally differentiated, 
dead, cornified, flattened cells (corneocytes). The corneocytes are composed of keratin 
intermediate filaments (KIFs) embedded in a filaggrin matrix and surrounded by insoluble 
lipids (ceramides, cholesterol, fatty acids, cholesterol esters, glucosylceramides and 
phospholipids) which play an important role in the barrier function of the epidermis because 
of their prevention to water loss. In addition, to reinforce the cornified envelope just below the 
plasma membrane, there are structural proteins (involucrin, loricrin, trichohyalin and small 
proline-rich proteins) synthesized and crosslinked by transglutaminases (TGase1, TGase3 and 
TGase5) (Eckert and Rorke, 1989; Steven and Steinert, 1994; Richard, 2004; Candi et al., 2005; 
Akiyama, 2011; Simpson, Patel, and Green, 2011). 
15 
 
 
Figure 2. Apoptosis and terminal differentiation in the epidermis. The proteins expressed 
in specific locations in the epidermis during skin differentiation are shown. Apoptosis is limited 
to the basal layer and cornification takes place in the suprabasal layers (Candi et al., 2005). 
 
Filaggrin (FLG) is formed from profilaggrin and is crosslinked to the epidermal cornified 
envelope. Its main function is to coordinate the structure of the cornified cells and it is rich in 
Arg and His residues (Candi et al., 2005). The profilaggrin system is proteolytically processed 
during keratinocytes differentiation (Aufenvenne et al., 2012) and participates in the alignment 
of KIFs, the control of significant changes in cell shape and the maintenance of epidermal 
texture. Involucrin is expressed throughout the suprabasal layers in stratified epithelia 
including epidermis. In humans, it consists mainly in Gly and Asp residues, and it is rich in α-
helices. Loricrin in humans is the main component of the epidermal cornified envelope in the 
epidermis and is expressed in the granular layer during cornification (the process of terminal 
keratinocyte differentiation). Loricrin is rich in Gly, Ser and Cys residues. Small proline-rich 
proteins (SPRs) are a 14-member multigene family formed by three subgroups: SPR1, SPR2 
and SPR3. The structure of SPRs is based in β-turn motifs and they contain heal and tail 
domains that are rich in Gln and Lys residues. In addition, a central domain of variable numbers 
of repeating peptide units of highly enriched in Pro residues is presented in SPRs. It has been 
suggested that these proteins act as bridges to join together other precursors (Candi et al., 2005; 
Eckert et al., 2005). 
Transglutaminases (TGase) are calcium-dependent enzymes that catalyze the formation of 
covalent bonds between the glutamyl residues and lysyl residues of either proteins or 
polyamines (Iizuka, Chiba and Imajoh-Ohmi, 2003), producing stable structures consisting of 
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polymerized proteins important in biological processes to maintain cell and tissue integrity 
(Yamada et al., 1997). 
 
The cornified lipid envelope (CLE) is composed of a monolayer of long chain, ω-acylated-
hydroxy-ceramides, with minor amounts of omega-hydroxy-fatty acids packaged, along with 
large amounts of other barrier lipids such as cholesterol and its esters, free fatty acids (FFA), 
and other ceramides (Cer) into their limiting membrane and central core (Figure 3). The 
insoluble proteins found in the cornified envelope are covalently bound to a layer of lipids, 
being these bonds ester linkages in which the carboxyl group of the arrayed glutamic acid (Glu) 
residues of involucrin is bound to the hydroxyl group of ceramides. At a later stage of 
differentiation, the lamellar body membranes unify with the apical plasma membrane, secreting 
the contents into the extracellular milieu. One of the products delivered into the plasma 
membrane are the ω-OH-Ce, generated by CYP4F22 (protein of the cytochrome-P450 family 
4) (Kalinin, Marekov, and Steinert, 2001; Lopez et al., 2007; Elias et al., 2014). 
CLE functions as a scaffold for the organization of the extracellular lamellar bilayers, as a 
semi-permeable membrane to transfer water and restricts the loss of hygroscopic molecules 
and contributes to the cohesion of the stratum corneum (SC) (Elias et al., 2014). 
17 
 
 
Figure 3. Generation of acyl-Cer and protein-bound Cer in epidermis. G, glucose; SB, 
stratum basale; SC, stratum corneum; SG, stratum granulosum; SS, stratum spinosum (Kihara, 
2016). 
 
The formation of the skin barrier is a complex process that involves a big number of proteins, 
lipids and enzymes. Mutations in genes that code for these molecules can result in diseases, 
such as autosomal recessive congenital ichthyosis (ARCI).  
 
1.1.2. PORCINE SKIN 
Biomedical research is extended and most of the studies carried out with animals in recent 
years have used the murine species due to their small size, fast reproductive cycles, and short 
lifespan. However, in many occasions murine species do not sufficiently act for human 
pathologies. In connection with the point previously mentioned, animals that better represent 
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human disorders are needed. Pigs and humans share many characteristics such as anatomy, size 
or physiology (Gutierrez et al., 2015).  
Although rats and mice have been used very often in skin wound healing research, murine 
models are not ideal due to them being loose skinned animals. They also present 
immunologically significant differences in both innate and adaptive immune system, which is 
not surprising due to their small size and lifespan (comparing to humans) (Mestas and Hughes, 
2004; O’Brien et al., 2014). Moreover, Wei et al. (2017) studied different mechanical 
properties and skin tissue structure in mice, pigs and humans, among others, observing similar 
skin strata thickness, and elastic and viscoelastic properties for pig and humans (in vivo), but 
thinner skin layers in mice.  
Animal skin is different morphologically comparing to human skin, respecting to epidermis 
and dermis thickness, hair follicles, and other characteristics (Figure 4). Porcine and human 
skin have many similarities such as histological, physiological and immunological 
characteristics, but also some differences concerning structure, immunohistochemistry, and 
function. Despite the dissimilarities, porcine seems to be the most appropriate animal type to 
substitute human skin when doing models for testing, even if rat, mouse, and rabbit have been 
used in dermatological and toxicological studies due to their availability, their small size and 
low cost. In addition, pigs are the favorite nonrodent species of choice in the preclinical 
toxicological testing of drugs. (Avon and Wood, 2005; Swindle et al., 2012; O’Brien et al., 
2014; Fujita et al., 2018). Drug in vitro permeability measurements and permeation studies 
have been carried out showing more similar results between pigs and humans than between 
mice and human beings (Todo, 2017). Pigs are therefore the major animal species used for 
translational research and they seem to be an alternative to the dogs or primates as nonrodent 
species used in research.  
The skin of the pig is slightly hairless and has a fixed subcutaneous layer and dermal hair 
follicle like humans. Their skin is thicker, varies in different anatomic locations, and it is less 
vascular comparing to human skin, being structurally similar to human epidermal thickness 
and dermal-epidermal thickness ratios. They have also sweat glands and sebaceous glands 
throughout the skin with minimal functions in thermoregulation. Pigs contain dermal collagen 
and elastic content that is more similar to human than other animals used in research. Also, 
they show similar epidermal turnover kinetics, lipid constitution and carbohydrate 
biochemistry, and a similar microbiome to human beings. Porcine models are therefore used in 
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wound healing, plastic surgery, reconstructive techniques, burn models, stem cell research and 
artificial skin for transplantation surgically, as they give a more similar anatomy of the skin 
(Eaglstein and Mertz, 1978; Swindle, 1998; Avon and Wood, 2005; Liu et al., 2009; Swindle 
et al., 2012; Gutierrez et al., 2015).  
 
 
Figure 4. Comparison between human, pig, rat and mouse skin. Paraffin skin sections from 
healthy humans, pigs, rats and mouse tissue were stained with haematoxylin and eosin for 
structural comparisons. EP, epidermis; DM, dermis; BD, blood vessel; SB, sebaceous gland; 
HF, hair follicle; AP, sweat gland; M, muscle (O’Brien et al., 2014). 
Nowadays, many researchers take in consideration porcine skin as an appropriate model to 
study human skin barrier and for pharmacological tests in vivo and in vitro.   
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Some researchers have studied the ear porcine skin through in vitro studies, using the pig ear 
as a model for human skin. Jacobi et al. (2007), for example, carried out studies with skin 
samples from different body areas (ear, back, abdomen, among others) for percutaneous 
absorption of substances that are applied topically, as the percutaneous absorption depends in 
vivo of the body region studied. Also, Sekkat, Kalia, and Guy (2002) evaluated the stratum 
corneum barrier function on porcine ear skin in vitro as a model for humans.  
Ideally, one would like to use human skin to evaluate penetration properties of candidate drugs, 
but not all researchers have access to get human skin samples (figu 1). That is the reason why 
some studies have compared human skin, human living skin equivalents, human reconstructed 
epidermis, and/or animal skin models (Schmook, Meingassner, and Billich, 2001; Herron, 
2009; Ranamukhaarachchi et al., 2016).   
Table 1. Advantages and disadvantages of human and porcine skin models (Abd et al., 
2016). 
Model Advantages Disadvantages 
Human skin:   
In vivo Gold standard 
Often precluded for ethical 
and practical reasons 
Ex vivo skin  
Best surrogate for in vivo 
humans 
Not readily available, 
variability 
Animal skin:   
In vivo 
 
Reasonably easy to obtain 
animals, can be scaled up to 
humans 
Pigs: similar barrier to 
humans, but difficult to 
handle 
Ex vivo skin Easy to obtain 
Different barrier properties, 
variability 
Reconstructed skin 
models: 
  
Reconstructed human 
epidermis 
Built-in barrier properties 
Usually more permeable 
than human skin 
Living skin equivalents 
Can be engineered to include 
a range of normal or disease 
characteristics 
Usually more permeable 
than human skin 
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1.2. ARCI 
1.2.1. CLASSIFICATION OF ARCI 
Ichthyosis form part of a clinical and etiological group of Mendelian disorders of cornification 
(MEDOC) involved all or most of the entire integument. During the last years, progress has 
been made to define the molecular basis of these disorders and to establish a genotype-
phenotype correlation. Nevertheless, there is not a classification of these diseases universally 
accepted. One of the revised classification (Table 2 and Table 3) is based on the diagnostic as 
main criteria for that classification, being nonsyndromic and syndromic ichthyosis the two 
subgroups. In nonsyndromic ichthyosis, the phenotypic expression of underlying genetic 
deficiency is only seen in skin, while in syndromic ichthyosis the deficiency is seen in skin and 
other organs (Oji and Traupe, 2009; Oji et al., 2010; Yoneda et al., 2016). 
Table 2. Subtypes of inherited ichthyosis: nonsyndromic forms (Takeichi and Akiyama, 
2016). 
Nonsyndromic ichthyosis 
Common 
ichthyosis 
ARCI Keratinopathic ichthyosis 
Ichthyosis 
vulgaris 
 
Recessive X-
linked ichthyosis 
Major types Minor types Major types Minor types 
Harlequin 
ichthyosis 
 
Lamellar 
ichthyosis 
 
Congenital 
ichthyosiform 
erythroderma 
Self-healing 
collodion baby 
(SHCB) 
 
Acral-SHCB 
 
Bathing suit 
ichthyosis 
Epidermolytic 
ichthyosis 
 
Superficial 
epidermolytic 
ichthyosis 
Annular 
epidermolytic 
ichthyosis 
 
Congenital 
reticular 
ichthyosiform 
erythroderma 
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Table 3. Subtypes of inherited ichthyosis: syndromic forms (Yoneda, 2016). 
Syndromic ichthyosis 
Netherton 
syndrome 
Sjogren-
Larsson 
syndrome 
Refsum syndrome 
Multiple sulfatase 
deficiency 
ichthyosis 
Keratitis-
ichthyosis-
deafness 
syndrome 
Conradi-
Hunermann-
Happle syndrome 
Dofman-
Chanarin 
syndrome 
Ichthyosis 
follicularis with 
alopica and 
photophobia 
Hystrix-like 
ichthyosis with 
deafness 
Congenital 
hemidysplasia 
 
ARCI is a genetically (Takeichi et al., 2015) heterogeneous group of keratinization disorders 
with an approximate prevalence of 1:100000 (Eckl et al., 2013; Pigg et al., 2016). Ichthyosis 
symbolize a group of cutaneous disorders with the common characteristic of abnormal 
epidermal differentiation. The word Ichthyosis comes from the Greek root ichthys, meaning 
fish, representing the cutaneous scaling presented in these disorders. These disorders are mostly 
nonsyndromic and limited to the skin (Fischer, 2009). They are characterized by abnormal skin 
scaling over the whole body, dry and thickened cornified layer (hyperkeratosis) (Oji and 
Traupe, 2009; Sugiura and Akiyama, 2015); and in many cases by inflammation presenting as 
erythroderma, for example, in bullous/keratinopathic ichthyosis (Oji and Traupe, 2009). The 
barrier function of the skin of these patients has a reduced capacity to protect against chemical 
and bacterial external components, and to prevent transepidermal water loss (Craiglow, 2013). 
It affects all racial groups and ethnic, and it is seen in more elevated incidence in societies in 
which consanguineous marriage is usual (Richard, 2017). 
 
Depending on their causative genes or loci, ARCI is classified into a total of 11 subtypes (Oji 
et al., 2010; Shigehara et al., 2016; Bastaki et al., 2017; Takeichi et al., 2017). The main ARCI 
phenotypes are harlequin ichthyosis (HI), lamellar ichthyosis (LI) and congenital 
ichthyosiform erythroderma (CIE) (Figure 5). 
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Harlequin ichthyosis is the most severe form of autosomal recessive congenital ichthyosis and 
has a high perinatal mortality. Patients with HI show thickened and scaly skin on their entire 
body, and babies are covered with an armour of hyperkeratosis (Oji et al., 2010; Vahlquist, 
2010; Maruthappu, Scott, and Kelsell, 2014; Numata et al., 2015; Sugiura and Akiyama, 2015). 
Other clinical characteristics of this form is eclabium (the turning outwards of a lip) and open 
mouth, ectropion (the eyelid is turned outwards away from the eyeball), hypoplastic fingers, 
and mobility limitation of the joints. In addition, these patients are at high risk for 
hypo/hyperthermia, dehydration, respiratory distress, and skin infection, among others (Salehin 
et al., 2013; Rathore et al., 2015; Shruthi et al., 2017).  It has a frequency of 1:1000000, and it 
is due to nonsense mutations in the ATP-binding cassette A12 (ABCA12) gene (Oji and Traupe, 
2009). 
Currently there is no cure for HI. However, treatment can be carried out thanks to the developed 
medical care and progresses in the postnatal therapies, such as use of systemic retinoids. 
ABCA12 gene mutations can be diagnosed in the fetus (Salehin et al., 2013; Mithwani et al., 
2014; Rathore et al., 2015), a first step for an early detection of the disease (Salehin et al., 2013; 
Mithwani et al., 2014; Tekin, 2014).  
Lamellar ichthyosis, also called as nonerythrodermic ichthyosis, causes severe abnormalities 
of the cornified layer. LI is characterized by the presence of a collodion membrane at birth 
covering the neonate, and large, dark, platelike, solidly adherent scales in the absence of 
erythroderma (Fischer et al., 2000; Louhichi et al., 2013; Richard, 2017).  Most of LI patients 
are born as collodion babies (CB), in a hyperkeratotic translucent membrane, and frequently 
present a characterised involvement of the face and the ears. Other features of these patients 
are ectropion, eclabion, palmar and plantar hyperkeratosis, and alopecia (Fischer et al., 2000; 
Akiyama, Sawamura, and Shimizu, 2003; Al-Naamani et al., 2013). Its incidence is about 
1:500000, and the most common cause of LI is inactivating mutations in the transglutaminase 
1 (TGM1) gene. A defect in cornification or terminal epidermal differentiation can be observed 
in the skin of LI patients (Fischer et al., 2000; DiGiovanna and Robinson-Bostom, 2003; 
Louhichi et al., 2013).  
Congenital ichthyosiform erythroderma is characterized by erythroderma with fine, white scale 
and often with palmoplantar hyperkeratosis (Al-Naamani et al., 2013; Sugiura and Akiyama, 
2015; Richard, 2017). Also, eclabion, ectropion, and loss of eyebrows and lashes, are shown 
more frequent in this form, comparing to LI. About 90% of CIE patients present as collodion 
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babies at birth. It is an inflammatory form of ichthyosis that affects 1:300000 of the population. 
In some cases, the erythroderma and fine scaling decrease with age when using treatments such 
as retinoids or steroids (Akiyama, Sawamura, and Shimizu, 2003; Fischer et al., 2000). 
 
Figure 5. Phenotype of ARCI-patients. (A) Neonato with HI (Glick et al., 2016). (B) Back 
and (C) dorsa of the feet of a CIE patient with fine, white scales and erythroderma (Akiyama, 
Sawamura, and Shimizu, 2003). (D) Collodion membrane in ARCI (Schmuth et al., 2013). (E) 
Leg and (F) dorsa of the feet of a LI patient with thick and dark brown scales without 
erythroderma (Akiyama, Sawamura, and Shimizu, 2003). 
 
In about 10% of collodion babies, the disease can either evolve to a mild form of ARCI or there 
is a long-term clinical healing. One of these clinical types is the self-improving congenital 
ichthyosis (SICI) that has been described in patients with mutation in TGM1 and those with 
12R-LOX and eLOX-3 deficiencies. Mutations in TGM1 related to temperature-sensitive 
activity can lead to bathing suit ichthyosis (BSI), also with collodion babies, but in this case 
the skin of the extremities “heals” in a long period of time (Vahlquist et al., 2010; Traupe, 
Fischer, and Oji, 2014; Takeichi and Akiyama, 2016).  
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1.2.2. GENETICS OF ARCI 
ARCI follows an inherited autosomal recessive pattern. Eleven genes are reported in 
association with different ARCI phenotypes: ABCA12, ALOXE3, ALOX12B, CERS3, 
CYP4F22, LIPN, NIPAL4, PNPLA1, SDR9C7, SULT2B1 and TGM1. In about 15% of families 
affected by ARCI, no mutations in any of the known genes have been identified (Richard, 
2017).  
ABCA12 gene is a keratinocyte lipid transporter ATP-binding cassette sub-family A member 
12, located in a region of chromosome 2q34 (Annilo et al., 2002). Mutations in this gene are 
associated with all three forms of ARCI (HI, LI, and CIE). While HI is usually related to loss 
of function gene, LI and CIE are associated with disease. ABCA12 transports lipids to cells 
that form the epidermis and the normal development of the skin, via lamellar granules. 
Lamellar granules reduction is shown in the skin of HI patients (Akiyama, 2010; Salehin et al., 
2013; Maruthappu, Scott, and Kelsell, 2014), as a result of which, abnormal lipid-containing 
vacuoles form in the cytoplasm of the corneocytes, producing a thickened and not desquamate 
stratum corneum (Hovnanian, 2015). Therefore, a defective ABCA12 leads to the disruption of 
lamellar granule lipid transport in the upper epidermal keratinocytes, and to the loss of the skin 
lipid barrier (Akiyama et al., 2005; Sugiura and Akiyama, 2015).  
Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are lipoxygenases (LOX) 
genes that are expressed in the epidermis and are located in the chromosome 17p13.1 (Jobard 
et al., 2002; Lefèvre et al., 2003). LOX oxygenates the linoleate moiety of ceramides, an 
important step for the synthesis of proteins of the cornified cell envelope and for the formation 
of the corneocyte lipid envelope, indispensables for barrier function and lipid metabolism of 
the skin. The genes for the human epidermal LOX are ALOX15B, ALOX12B, and ALOXE3, 
and mutations in ALOX12B and ALOXE3 are linked to cases of CIE, LI or CB (Eckl et al., 
2005; Eckl et al., 2009; Akbari and Ataei-Kachoui, 2015; Sugiura and Akiyama, 2015; Dick et 
al., 2017). There are also studies in which a possible participation of ALOX15B in ARCI has 
been investigated (Lesueur et al., 2007). 
CERS3 encodes ceramide synthase 3, is located in the chromosome 15q26.3, and is involved 
in the combination of ceramides with very long-chain acyl parts. The deficiency in the 
metabolism of sphingolipids disorders the composition of lipids present in the epidermis, 
causing irregularities in the terminal differentiation (Radner et al., 2013; Kihara, 2016). 
Mutations in this gene are associated to LI patients. Human CerS3 is usually present in testis 
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and skin, specifically in the zone that marks the junction of stratum granulosum and stratum 
corneum (Eckl et al., 2013). Eckl et al. (2013) found the malfunction in ceramide synthesis 
only in diseased keratinocytes that were in the late stages of the differentiation. 
Defects in CYP4F22 (protein of the cytochrome-P450, family 4, subfamily F, polypeptide 22), 
which encodes an epidermal ω-hydoroxylase decisive in the formation of acylceramides 
(Gruber et al., 2017), are related to LI and CB (Noguera-Morel et al., 2016). It is situated in the 
chromosome 19p13.12. Patients with mutation in this gene are born without collodion 
membranes, but they develop the ARCI phenotype later (Binamer, 2016). Ichthyosis-mutant 
proteins show a decrease of enzyme activity, which means that there is an association between 
activity and pathology. In addition, the acylceramide production in these patients is reduced 
(Ohno et al., 2015).   
LIPN gene, which encodes lipase N, is thought to play a role in the differentiation of human 
keratinocytes. It is located on 10q23.31 locus and present in LI patients (Israeli et al., 2011; 
Ohno et al., 2015).  
NIPAL4 (NIPA-like domain-containing 4) encodes for ichthyin, a protein proposed to be a 
magnesium transporter, a transmembrane receptor implicated in the formation or transport of 
lamellar bodies, and a membrane receptor for lipoxygenase products. It is located in the 
chromosome 5q33, and mutations have been identified as defects in LI or CIE phenotypes 
(Dahlqvist et al., 2007; Wajid et al., 2010; Li et al., 2013; Gruber et al., 2017). These patients 
are born either with or without collodion membrane, with fine brown scales on erythematous 
background with keratoderma and probable atopic diathesis (Binamer, 2016).  
PNPLA1 (patatin-like phospholipase domain protein 1) has been identified as causative gene 
of ARCI, in particular in LI patients, and it is formed by eight exons at chromosome 6p21.31. 
PNPLA1 plays an important role in lipid synthesis and metabolism during epidermal barrier 
formation, and its loss affects to the epidermal ceramide homeostasis (Oji and Traupe, 2009; 
Grall et al., 2012; Sugiura and Akiyama, 2015; Grond et al., 2016; Richard, 2017). Specifically, 
PNPLA1 is related to the synthesis of ω-O-acylceramides, which are involved in epidermal 
cornified lipid envelope organization (Dökmeci-Emre et al., 2017).  
SCR9C7 (short chain dehydrogenase/reductase family 9C, member 7) gene on chromosome 
12q13.3 participates in the conversion of retinal into retinol. Mutations in this gene have been 
found in LI and CIE patients. It is highly expressed in the granular and cornified layers of 
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normal human skin, which means that mutation in SCR9C7 submits an important role of 
vitamin A metabolism in terminal differentiation of the epidermis in humans (Shigehara et al., 
2016; Karim, Murtaza, and Naeem, 2017; Takeichi et al., 2017).  
SULT2B1 (Sulfotransferase family 2B, member 1) enzyme is a member of the cytosolic 
sulfotransferase superfamily that interacts in the synthesis and metabolism of steroids in 
humans. It is located on chromosome 19q13.33, and consists of two isoforms, SULT2B1a and 
SULT2B1b. The first isoform has not been detected in skin, while the isoform SULT2B1b is 
expressed in the human epidermis. It plays an important role in epidermal cholesterol 
metabolism and it participates in the maintenance of a functional cutaneous permeability 
barrier. Mutations in this gen cause ARCI, and the loss of SULT2B1 also affects the proper 
expression of cornified envelope proteins (Falany et al., 2006; Heinz et al., 2017). 
TGM1 gene spans 15 exons (Louhichi et al., 2013) (Figure 6), and it encodes transglutaminase-
1 (TGase1), a tissue-specific enzyme (Yamada et al., 1997) located at chromosome 14q11.2 in 
humans (Terrinoni et al., 2012). This enzyme has 817 amino acid residues, its molecular weight 
is approximately 89 kD, and is modified by myristoyl and palmitoyl adducts near the N-
terminus of the protein (Terrinoni et al., 2012; Louhichi et al., 2013; Vaigundan et al., 2014). 
TGase1 expression is differentiation-dependent and it initiates in the spinous layer (Eckert et 
al., 2005). Therefore, TG is expressed in the upper spinous and granular layers below the 
stratum corneum of the epidermis and in hair follicles and is linked to the inner plasma 
membrane of keratinocytes (Yamada et al., 1997; Terrinoni et al., 2012; Aufenvenne et al., 
2013; Vaigundan et al., 2014), being also involved in the formation of the cornified cell 
envelope (Farasat et al., 2009). TGM1 mutations cause LI and CIE phenotypes, and it also 
causes self-healing collodion baby (SHCB), a baby who is born as a collodion baby, but 
improves spontaneously (Oji and Traupe, 2009; Richard and Bale, 2014; Sugiura and Akiyama, 
2015). 
 
Figure 6.  Schematic illustration of genomic organization of TGM1 (Herman et al., 2009). 
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Other transglutaminases such as TGase3 or TGase5 are also present in different epidermal 
layers, but they cannot compensate the need of an active TGase1 in ARCI patients (Eckert et 
al., 2005; Aufenvenne et al., 2013). 
 
1.2.3. THERAPEUTIC STRATEGIES 
So far, the current available treatment for ARCI is symptomatic, and it is usually focused on 
patient’s experience instead of disease pathogenesis. One of the main objectives in this kind of 
treatment is to keep the skin hydrated. For that, humidification with long baths are used to 
hydrate and facilitate scale removal by abrasives such as sponges. In neonates with congenital 
phenotypes, intensive care using humidified incubators is necessary. With these incubators, 
temperature instability and hypernatremic dehydration is avoided. In addition, vigilance to 
check possible cutaneous infections is important. For the skin care, petrolatum-based creams 
and ointments are used. When infants become older, and with the course of the disease, therapy 
is based in long baths, keratolytic agents such as urea preparations, and lubrication for the 
hydration of the stratum corneum. Some locations, like the outer ear canals or regions of hair 
growth, need special care and professionals to help with regular removal of scaling. 
Furthermore, there are some measures to have in consideration: prevention of infection in the 
newborn, prevention of dehydration, maintenance of body temperature, and high caloric diet, 
among others. In addition, skin irritants should be avoided (DiGiovanna et al., 2013; Schmuth 
et al., 2013; Richard, 2017). 
Another therapy for ARCI patients is the modulation of epidermal differentiation by nuclear 
hormone receptor ligands such as topical vitamin A, topical and oral retinoids. Retinoids are a 
family of natural and synthetic compounds that share structural and functional characteristics 
with vitamin A. Retinoids are helpful in some locations including palms, soles and eyelids, for 
the treatment of ectropion. However, before starting retinoids treatment, some details from the 
patients like age, severity or psychological status have to be considered. Other factor to be 
taken into consideration is the type of retinoids, being the most common used etretinate, 
acitretin and isotretinoin. Depending of the chosen retinoid, the dose will vary, even if the goal 
of choosing a dose should be to find the lowest dose that the patient tolerates. One of the 
limitations of the treatment with retinoids is that the scaling comes back if the treatment is 
stopped. They are also highly teratogenic; it can disturb the development of the embryo or 
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fetus, so it should not be used in pregnant women or women planning a pregnancy. In addition, 
adverse effects such as hair loss, abnormalities in blood cell counts, neuromuscular effects like 
headache, renal dysfunction when using etretinate or bone toxicity may appear (Larsen et al., 
1988; Mukherjee et al., 2006; Verfaille, Borgers, and Van Steensel, 2008; Layton, 2009; 
Ormerod, Campalani, and Goodfield, 2010; DiGiovanna et al., 2013; Mortazavi et al., 2013; 
Schmuth et al., 2013).  
Another kind of treatment is the administration of agents like liarazole, that is a novel imidazole 
derivative that seems to block the metabolism of retinoic acid by inhibition of the cytochrome 
P450-dependent 4-hydroxylation of retinoic acid, which is the physiological breakdown of all-
trans-retinoic acid. Blocking the metabolism of retinoic acid, tissue levels of it increase. This 
treatment seems to be better tolerated in patients and shows less adverse effects (Lucker et al., 
1997; Verfaille et al., 2007; Verfaille, Borgers, and Van Steensel, 2008).  
As it has been mentioned above, available treatments only provide symptomatic relief to the 
patients, but they do not eliminate them. Therefore, a causative treatment has to be developed.  
One way to find a causative treatment is by protein substitution. Aufenvenne et al. (2013) 
developed a targeted topical enzyme-replacement therapy for TGase1-deficient ARCI, for what 
a carrier system tagged is necessary. This carrier system is a liposome that delivers the 
recombinant human TGase1 enzyme at the site of action into keratinocytes in a skin-humanized 
mouse model for TGase1-deficient ARCI. In addition, Stout et al. (2014) described the topical 
introduction of recombinant FLG monomer protein linked to a cell penetrating peptide, for the 
treatment of ichthyosis vulgaris, which is a disorder of keratinization with mutations in 
filaggrin. They demonstrated this in FLG deficient animal model.  
Liposomes can be unstable under environmental stress such as high temperature or high 
pressure. An alternative for these described carrier systems are the dendritic polyglycerol (PG) 
and poly(N-isopropylacrylamide (PNIPAm)-based nanogels. Dendritic molecules such as 
polylysine, polyester, polyamidoamine, triazine dendrimers, and polyglycerol are being used 
for biomedical studies to amplify or multiply pathopharmacological effects. PGs are water 
soluble, polyether-based and spherical nanomaterials with low anticoagulative and intrinsic 
anti-inflammatory function. PGs are obtained by ring-opening polymerization of glycerol, and 
stimuli-sensitive nanogels are polymeric particles formed by a cross-linked, three-dimensional 
network that can respond to local environmental conditions. By other side, PNIPAm is a 
nontoxic thermoresponsive polymer with inverse solubility and a reversible phase transition 
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upon heating. The use of PNIPAm in the biomedical field has been limited due to its deficiency 
of water solubility, and because it is not specific to protein absorption. However, PNIPAm has 
shown very positive results concerning temperature-sensitive applications, as it is soluble at 
room temperature, but its phase separates at body temperature (37oC) (Calderon et al., 2010; 
Cuggino et al., 2011; Lima, Morales, and Cabral, 2016; Pant et al., 2017). Witting et al. (2015) 
prepared protein-loaded thermoresponsive PNIPAM-dPG nanogel (Figure 7) for cutaneous 
protein TGase1 delivery in TGM1-knock -human skin model restoring the skin barrier function.  
 
Figure 7. Synthesis and chemical structure of the PNIPAM-dPG nanogels (Witting et al., 
2015). 
 
1.3. SKIN MODELS 
One of the main issues for the cosmetic industries has been the in vitro engineering of the 
human skin due to ethical and legal requests. Biomedical and pharmacological research also 
requires suitable test methods for the discovery of drugs and treatments. Two-dimensional (2D) 
skin cell cultures have been used since many years now, but main functions of skin such as 
barrier function, cell layering, or immune function are not summarized in these 2D cultures. In 
vitro human skin equivalents (HSE) are used for drug development, as the skin can be used to 
test systematically acting drugs, and for efficacy testing of drugs at sites of acting thanks to the 
construction of disease skin models (Mertsching et al., 2008; Mathes, Ruffner, and Graf-
Hausner, 2014; Klicks et al., 2017). Human skin equivalents are therefore also used to study 
normal and abnormal skin biology, including infection, skin disease, and wound healing; and 
they constitute an alternative method to animal testing (Vörsmann et al., 2013; Abdallah, 
Pawar, and Harrad, 2015; Reijnders et al., 2015).  
Human skin equivalents are three-dimensional (3D) organotypic models of the human skin, 
bioengineered substitutes, constituted of primary human skin cells (keratinocytes, fibroblasts 
and/or stem cells) and components of the extracellular matrix. After particular culture 
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conditions, a HSE can resemble the majority of the characteristics of the native human skin (El 
Ghalbzouri et al., 2009; Zhang and Michniak-Kohn, 2012; Planz, Lehr, and Windbergs, 2016; 
Mieremet et al., 2017).  Specific advantages of these models include normal human cells, 
organotypic structure, barrier function, and real-life exposure options, among others (Leist et 
al., 2012).  
Different systems can be used to create skin models. Some of these systems are: spheroids, 3D 
bioprinting, organ-on-a-chip, and hydrogels.  
Spheroids or aggregates are formed by cells within a matrix, on a matrix, or in a suspension 
medium. 3D spheroids constitute cells in various stages including proliferating, apoptotic and 
necrotic cells, among others. These models are constructed using HaCaT cells or fibroblasts 
co-cultured with melanoma cells in the spheroid format to obtain tumor models and are useful 
for cancer research and development of treatment. However, some of their limitations are the 
complexity, variety and heterogeneity of the human tumor environment (Fennema et al., 2013; 
Edmonson et al., 2014; Chatzinikolaidou, 2016; Klicks et al., 2017).  
Other technology is 3D bioprinting, that is based on three main approaches: design and 
production of materials or/and structures, replication of biological tissue using embryonic 
organ development, and the construction of small and functional blocks. Basically, it consists 
on the printing of different layers of a desired material such as hydrogel or biodegradable 
scaffolds to form those architectures. Cells can be added on these geometries to form biological 
structures. In addition, thanks to that system, structures like 3D neural tissues or tumor cell-
bearing tissues for angiogenesis model can be created (Murphy and Atala, 2014; Klicks et al., 
2017; Xia, Jin, and Ye, 2018).  
Organ-on-a-chip system is the remodeling of tissue and organs by culturing living cells in a 
microscale environment controlling space and time. The aim of this technology is not to create 
a whole living organ, but rather to build a minimal functional unit that sum functions of tissue 
and organs. Skin organ-on-a-chip, for example, can be used to test drugs crossing through the 
stratum corneum (Klicks et al., 2017; Ronaldson-Bouchard and Vunjak-Novakovic, 2018).  
However, the principal technique for constructing the models is the use of hydrogels to form 
the scaffold for dermal fibroblasts, that is co-cultured with keratinocytes on the surface. 
Collagen I is the most used hydrogel material. In addition, hydrogel systems are used to build 
full thickness human skin models (FTM), a generally used of HSE. FTM is formed by primary 
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fibroblasts in the dermal equivalent and primary keratinocytes in the epidermal equivalent 
growing on collagen I matrices, using filter inserts and multiwell culture plates. In these 
models, the fibroblast-keratinocyte communication is indispensable for epidermal 
morphogenesis and formation of the basement membrane (Breitkreutz et al., 2013; Klicks et 
al., 2017; Mieremet et al., 2017). FTM can be used for the study of skin disorders. In recent 
years, a diversity of reconstructed human epidermis models and full thickness human skin 
models, such as Phenion Full Thickness Skin Model, have been developed (Ackermann et al., 
2010). Some other researchers have developed three-dimensional artificial skin models for 
disorders of keratinization like psoriasis and Harlequin ichthyosis (Thomas et al., 2009; Duque-
Fernandez et al., 2016). Also, Eckl et al. (2011) developed 3D human skin models for 
autosomal recessive congenital ichthyosis in 2011, using TGM1-Knock Down models (Figure 
8).    
 
Figure 8. Full thickness skin models. 
 
1.4. SKIN EXPLANTS 
For ethical reasons, the use of experimental animals for some studies such as skin irritation for 
cosmetic products or chemical substances is not desired. Due to that, new alternative methods 
are required. Some of these methods use human keratinocyte culture to study the metabolism 
of dimethyl-thiazoldiphenyltetrazolium bromide (MTT) by cellular lactate dehydrogenase 
(LDH) connections or neutral red from preloaded cells. But those methods have disadvantages 
such as the fact that they have to be made in a short time range and only diluted products are 
used. A new method has been proposed and it is the use of human organotypic skin explanted 
culture (hOSEC). hOSEC are models similar to in vivo human skin, as a 3D human skin model, 
formed by melanocytes, keratinocytes, Langerhans cells, and the entire structure of fibroblasts, 
collagen and glycosaminoglycans. These characteristics are important, and they differ from the 
3D skin models, that are only made of fibroblasts and keratinocytes on an extracellular matrix. 
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Also, skin biopsies can be kept for several days or weeks in culture medium when incubated at 
37oC in an atmosphere of 95% air and 5%CO2.  This system permits the application of creams, 
ointments and substances that are lipid-soluble, and the study of the homeostasis and 
inflammatory/immune reactions. (Nakamura et al., 1990; Kataranovski and Karadaglic, 1999; 
Varani et al., 2007; Varani, 2012; Andrade et al., 2015; Frade et al., 2015).  
Human skin in large quantities is not usually available, reason why other alternatives have to 
be found. Skin organ-culture systems from different animal species like rodents, rabbits and 
pigs, have been described and used for biochemical studies (Bartnik et al., 1990; Jacobs et al., 
2000; Varani et al., 2002; Dame et al., 2009).  
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2. AIM OF THE STUDY 
Symptomatic treatment including a daily and time consuming strict routine of bathing with 
removal of excess skin scales and recurrent moisturising of the whole body gives some relieve 
to the ARCI (a rare cornification disorder) patients. However, this is not enough, as these 
available treatments only relieve the symptoms, but they do not eliminate them. A causative 
therapy is therefore necessary for these patients, and a causative treatment like the substitution 
of the diseased protein would mean an increase of the quality of life. 
TGM1 is the major gene in which mutations can cause ARCI, due to damaged linkage of lipids 
and proteins in the upper layer of the epidermis, and consequently the disturbance of the 
epidermal barrier. Therefore, TGM1 is the gene chosen as a first target to test the possible 
replacement of the protein. Dendritic molecules, such as polyglycerol or polyester, have been 
shown to be useful as potential carriers in biomedical and pharmaceutical areas. TGase1 protein 
was previously loaded onto the developed PNIPAM-dPG nanogel for the delivery of the 
therapeutic protein in the epidermis, and its effectiveness has been studied. PNIPAM-dPG 
nanogel is a novel biocompatible thermoresponsive nanocarrier expected to be advantageous 
for epidermal deliveries due to its temperature responses.  
The main goal of this project is the study of the fate of the protein-loaded thermoresponsive 
PNIPAM-dPG nanogel for cutaneous protein TGase1 delivery in skin model restoring the skin 
barrier function in ARCI patients with TGM1 mutation.  
To accomplish this, the construction of three-dimensional skin models built by primary 
keratinocytes and dermal fibroblasts will be carried out. These models mimic the architectural 
features and behaviour of human skin, therefore they are supposed to be useful for the 
development of patient-specific 3D skin models. Following this way, the molecular features of 
the diseases can be replicated, and the restoration of epidermal function with the TGase1/NG 
complex can be studied. 
In parallel, studies with primary keratinocytes grown in a 2D monolayer will be performed to 
study the expression of different genes during epidermal differentiation, and also the specific 
subcellular location of the therapeutic protein and carrier when they are delivered to 
keratinocytes.  
Due to the difficulties to obtain human skin samples, these studies will be also carried out with 
pig skin samples, as human and porcine skin share many similarities like histological, 
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immunological and physiological characteristics. In this way, we could compare the delivery 
of the TGase1 protein and the nanogel in our 3D skin models to its fate in ex vivo skin resulting 
from the culture of skin explants.   
With this project we expect to better understand how the designed protein-loaded 
thermoresponsive PNIPAM-dPG nanogel for cutaneous protein TGase1 delivery, and the 
protein TGase1, are being delivered in the epidermis, as this would have a great impact towards 
a causative therapy for ARCI.  
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3. MATERIALS AND METHODS 
3.1. ETHICAL APPROVAL 
The study was approved by the Research Integrity and Ethics Committee from the University 
of Huddersfield (Huddersfield, United Kingdom).  
All human primary cells lines used in this project were extracted and amplified from skin 
biopsies obtained after informed consent of healthy donors in accordance with Declaration of 
Helsinki. Three human cell lines were used, two of them were obtained from the Huddersfield 
Hospital in collaboration, and the other cell line was purchased in Lonza. 
Patient samples were provided by the Department of Dermatology, Medical University of 
Innsbruck, Austria, after obtaining written informed consent. The study was approved by the 
Institutional Review Board (Ethics Committee) of the Medical University of Innsbruck. 
Porcine cell lines were obtained from adult pigs from a Spanish abattoir located in Galaroza 
(Matadero de Jabugo-Galaroza), after permission from the Ethics Committee from the 
University of Huddersfield.  
 
3.2. MATERIALS 
Reagents and components: 
Reagents Company Order ID 
500 mL Filter-System Corning 430758 
Adenin Sigma A2786-5G 
Albumin Fraction V, protease free (BSA) CarlRoth T844.3 
Bacillol-AF Hartmann 973389 
Betaisodona Mundipharma 15.973 
Biopsy Punch 8mm PFM 48601 
CaCl2 Sigma C2661-500G 
Cell Safe Biopsy Capsules Leica 14039430014 
Cell strainer 100µm Corning 352360 
Cell strainer 70µm Corning 352350 
Cholera Toxin from Vibrio cholera (CT) Sigma C8052-1MG 
Collagenase D Roche 11088866001 
Cryo-Embedding NEG50 ThermoFisher Scientific 6502 
DAPI Sigma 10236276001 
Deep 6 well plate Corning 355467 
Dimethylsulfoxid (DMSO) Rotipuran CarlRoth 4720.4 
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Dispase II  Roche 04942078001 
Distilled water (DNase/RNase free) Gibco 10977-035 
DMEM  Gibco 11960-044 
DMEM F12 (1:1) (1x)  Gibco 21331-020 
DPBS (1x) Gibco 14190-094 
Entellan®  Sigma 1079610100 
Eosin CarlRoth X883.2 
Ethanol absolute Acros Organics 445740010 
Fetal Bovine Serum (FBS) Gibco 10270-106 
Fluoromount Aqueous Mounting Medium  Sigma  F4680-25ML 
Formalin neutral solution salt buffered pH 7 VWR chemicals 351638K 
Fungizone Amphotericin B Gibco 15290-026 
Gentamicin (10mg/mL) Sigma G1272-100mL 
Hämalaun Lsg, sauer nach Meyer CarlRoth T865.3 
HBSS (10x) Gibco 14180-046 
Histo-cassettes Leica 14039440000 
Human Epidermal Growth Factor (EGF) Sigma E9644-.2mg 
Hydrocortisone (HC) Sigma H0888-1G 
Inserts (high tensity, translucent PET membrane) Corning 353092 
Insulin from bovine pancreas Sigma I1882-100mg 
Keratinocyte Basal Medium (KBM) Lonza CC-3101 
KGM Single Quot Kit Supplements and Growth 
Factors 
Lonza CC-4131 
L-Glutamine 200mM (100x) Gibco 25030-123 
LysoTracker Deep Red  Invitrogen L12492 
Metal lids for histo-cassettes Leica 14039441014 
NaOH Sigma 71687-100G 
Paraffin Leica 037432124 
PBS pH 7.2 (1x) Gibco 20012-019 
Penicillin-Streptomycin (P/S) Gibco 15140-122 
Poly-L-Lysine hydrobromide  Sigma P1399-25MG 
ProFreeze NAO/CD Freeze (2x) Lonza 12-769E 
Pure Col Type I Bovine Collagen  Advanced BioMatrix 5005-100mL 
Scalpel Braun 5518016 
TaqMan® Fast Universal PCR Master Mix (2X) Applied Biosystems 4364103 
TaqMan® Gene Expression Assays* Applied Biosystems 
4351370 
(GAPDH) 
4331182 (others) 
Triton X-100 CarlRoth 3051.3 
Trypsin EDTA 0.05% (1x) Gibco 25300-096 
Trypsin Inhibitor Soybean Gibco 17075-029 
Tween 20 CarlRoth 9127.1 
Xylene pure Acros Organics 383930050 
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Kits:  
Kit Company Order ID 
High-Capacity RNA-to-cDNATM Kit Applied biosystems 4387406 
PureLinkTM RNA Mini Kit Ambion 12183018A 
 
Antibodies:  
Antibodies Dilution Isotope Company Order ID 
Anti-Mouse Involucrin 1:100 Monoclonal IgG1 Genetex GTX17610 
Anti-Mouse TGase 1  1:100 Monoclonal IgG2a Santa Cruz Sc-1664674 
Anti-Rabbit K10 1:150 Polyclonal IgG abcam ab53124 
Goat anti-Mouse  
Alexa Fluor® 633 
1:1000 Polyclonal IgG Invitrogen A21050 
Goat anti-Mouse 
Alexa Fluor® 546 
1:400 Polyclonal IgG Invitrogen A11003 
Goat anti-Rabbit  
Alexa Fluor® 546 
1:400 Polyclonal IgG Invitrogen A11035 
Mouse anti-E-cadherin 1:50 Monoclonal IgG2a BD Biosciences 610181 
Mouse anti-EEA1 1:50 Monoclonal IgG1 BD Biosciences 6120456 
Mouse anti-GM130 1:50 Monoclonal IgG1 BD Biosciences 610822 
 
TaqMan® Gene Expression Assays: 
TaqMan® Gene Expression 
Assays 
Details Assay ID 
ALOX12B 
Specie: Human; Transcripts: 1; Amplicon 
Length: 73; Location Chromosome: Chr.17: 
8072636-8087703; Gene Aliases: 12R-LOX, 
ARCI2 
Hs00153961_m1 
ALOXE3 
Specie: Human; Transcripts: 2; Amplicon 
Length: 112; Location Chromosome: 
Chr.17: 8095900-8118916; Gene Aliases: 
ARCI3, E-LOX, eLOX-3, eLOX3 
Hs00222134_m1 
GAPDH (Housekeeper) 
Specie: Human; Transcripts: 2; Amplicon 
Length: 122; Location Chromosome: 
Chr.12: 6534405-6538375; Gene Aliases: 
G3PD, GAPD, HEL-S-1623eP 
Hs99999905_m1 
TGM1  
Specie: Human; Transcripts: 1; Amplicon 
Length: 99; Location Chromosome: Chr.14: 
24249114-24263210; Gene Aliases: ARCI1, 
ICR2, KTG, LI, LI1, TGASE, TGK 
Hs01070310_m1 
TGM1 
Specie: Human; Transcripts: 1; Amplicon 
Length: 86; Location Chromosome: Chr. 14: 
24249114-24263210; Gene Aliases: ARCI1, 
ICR2, KTG, LI, LI1, TGASE, TGK 
Hs00165929_m1 
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3.3. METHODS 
3.3.1. CELL CULTURE 
The growth of primary cells, human and porcine primary cells, as well as cell culture 
experiments have been carried out. An overview of the reagents used for the culture of these 
cells can be seen in Table 4.  
Table 4. Reagents used in cell culture (companies mentioned above in chapter 3.2). 
Category and use Culture medium and its content Final 
concentration 
Basal Keratinocytes 
grown feeder free. 
KGMTM 
100% of KBMTM Basal Medium 
100% of KGMTM SingleQuotKit Supple-
ments and Growth Factors (BPE, hEGF, 
insulin, HC, GA-100) 
 
Basal Keratinocytes 
grown on feeders.  
KCM: 
43% of DMEM/F12 
43% of DMEM 
10% of FBS 
2% of L-Glutamine 
1% of Penicillin-Streptomycin 
1% of Hydrocortisone 
1% of hEGF 
0.1% of Insulin 
0.1% of Adenin 
0.01% of Cholera Toxin 
 
 
 
 
4 mM 
100 U/mL 
400 ng/mL 
10 ng/mL 
5 µg/mL 
0.018 mM 
10 ng/mL 
Fibroblasts and 3T3-J2 
feeders growth 
3T3-CM: 
88% of DMEM 
10% of FBS 
1% of L-Glutamine 
1% of Penicillin-Streptomycin 
 
 
 
2 mM 
100 U/mL 
Porcine skin explant 
growth 
PECM: 
95.5% of DMEM 
1% of Penicillin-Streptomycin 
1% of Hydrocortisone 
1% of L-Glutamine 
1% of Fungizone 
0.5% of Gentamicin 
 
 
100 U/mL 
100 µg/mL 
292 µg/mL 
2.5 µg/mL 
50 µg/mL 
Transportation of skin 
samples 
TPM (Transportation Medium): 
86.8% of DMEM 
10% of FBS 
2% of Fungizone 
1% of Penicillin-Streptomycin 
 
 
 
5 µg/mL 
100 U/mL 
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0.2% of Gentamicin 20 µg/mL 
Washing skin samples AA-PBS (Wash-Buffer): 
96.8% of PBS 
2% of Fungizone 
1% of Penicillin-Streptomycin 
0.2% of Gentamicin 
 
 
5 µg/mL 
100 U/mL 
20 µg/mL 
Freezing cells Freezing medium: 
90% of ProFreeze NAO/CD Freeze Media 
10% of DMSO 
 
Stopping trypsin/EDTA 
activity when splitting 
keratinocytes feeder-
free 
Trypsin inhibitor: 
500 mL of DPBS 
0.125 mg of Trypsin Inhibitor Soybean 
 
Differentiation of 
keratinocytes 
KGMTM  
0.114% of CaCl2 for human keratinocytes 
0.095% of CaCl2 for pig keratinocytes 
 
1.2 mM 
1 mM 
 
3.3.1.1. ISOLATION OF HUMAN AND PORCINE PRIMARY SKIN CELLS  
Human skin samples were extracted from biopsies, and pig skin samples were collected from 
a Spanish abattoir. The samples were transported in 50 mL Falcon tube with cold transportation 
medium (TPM) and then it was washed once in the laboratory with Betaisodona solution for 2-
3 minutes, followed by three wash steps in AA-PBS for 7 minutes.  
The sample was placed with epidermal side down in a petri dish, and some drops of AA-PBS 
were added until sample was lightly covered. The fat and hair were removed with some 
scissors. The sample was then cut using a biopsy punch instrument and placed in a new petri 
dish, epidermis side down. 2 mL of Dispase II solution were mixed with 18 mL of KGM 
(dilution 1:10) in a Falcon tube and then added until sample was submerged. 
The petri dish was placed overnight in a fridge (4oC). 
At the same time, 3T3 feeders were plated in 6-well plates for the keratinocytes culturing next 
day.  
 
The following day, dermis and epidermis were separated using two pairs of forceps. If the 
separation was not easy, the sample was placed in the incubator at 37°C, 5% CO2 level and 
95% relative humidity (RH) for 2 hours. The epidermis was placed in the lid of a 6 cm petri 
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dish filled with some drops of trypsin/EDTA and left for 10 min at room temperature (RT). 
The sample was minced, and trypsin activity was stopped with some mL of trypsin inhibitor. 
Everything was transferred to a 50 mL Falcon tube and centrifuged at 1000 rpm for 4 min at 
RT. At the same time, medium was removed from the feeder cell plates and KCM was added. 
Pellet was resuspended in 10 mL of KCM medium and filtered through a 70 µm cell stainer. 
The cells from the epidermis were plated in the 6-well plates. 
During trypsin-incubation, the dermal part of the sample was placed in a new petri dish, added 
some drops of collagenase D solution, until submerged, and placed in an incubator at 37°C, 
5% CO2 level and 95% RH until the next day. 
 
At the next day, medium was changed for the keratinocytes. Collagenase D solution was 
removed for dermal specimen, washed once with PBS, and added trypsin/EDTA until all 
dermis was fully covered. Dermis was cut in very small pieces and samples were left for 10 
minutes at room temperature in trypsin. The sample was minced using scalpels, trypsin activity 
was stopped with 3T3 culture medium, and the solution was transferred to a 50 mL Falcon 
tube. The sample was centrifuged at 1000 rpm for 4 min at RT, resuspended with 10 mL of 
3T3 culture medium, filtered through a 100 µm cell stainer and cells were plated in T25 flasks.  
On first day, medium was changed for the fibroblasts. For the first week, medium was changed 
for keratinocytes every third day, and for fibroblasts when necessary (Figure 9). 
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Figure 9. Schematic representation of extraction of pig skin cells. 
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3.3.1.2. SPLITTING FIBROBLASTS 
Fibroblasts were thawed and resuspended in 3T3 culture medium in a Falcon tube for the 
plating. Cells were mixed carefully and incubated at 37°C, 5% CO2 level and 95% relative 
humidity. 
When cells were confluent and ready for splitting, the medium was removed and washed once 
with 25 mL of PBS 1x. 10 mL of Trypsin were added to the flask, which was incubated at the 
same temperature, CO2 and RH until cells were completely detached. Once cells were 
detached, 10 mL of media were added to inactivate Trypsin activity. All volume was collected 
to a Falcon tube and centrifuged for approximate 4 minutes at 1000 rpm, pellet was resuspended 
in 20 mL of media, and cells were counted with Neubauer chamber. To count the cells, the 
cover slip was placed on chamber, and the cell-Trypan Blue mix (10 µL) was transferred into 
counting chamber. The cell-Trypan Blue mix was prepared adding 20 µL of well-mixed cell 
suspension to 20 µL of Trypan Blue in an Eppendorf tube. The desired density and the correct 
media were added to each new flask. Cells were placed in the incubator at 37°C (Figure 10).  
 
Figure 10. Schematic representation of splitting. 
 
3.3.1.3. SPLITTING KERATINOCYTES 
The protocol carried out to split keratinocytes was similar to the one used to split fibroblasts. 
Keratinocytes were growing in dishes so when cells were confluent and ready for splitting, 
KGM medium was removed and washed once with 4 mL of PBS 1x. 5 mL of Trypsin were 
added, and cells were incubated at 37°C until cells were detached. After that, 10 mL of trypsin 
inhibitor medium were added to inactivate Trypsin activity. All volume was collected to a 
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Falcon tube and centrifuged for 4 minutes at 1000 rpm. Pellet was resuspended in 10 mL of 
media. The desired density and the correct media were added to each new dish. Cells were 
placed in the incubator at 37°C. 
 
3.3.1.4. TREATMENT WITH MITOMYCIN C 
Embryonic 3T3-J2 fibroblasts were used as feeder cells to support the growth of primary 
keratinocytes in culture. To inhibit the feeder layer growth in long-term culture, embryonic 
fibroblast feeder cells were treated with Mitomycin C. The Mitomycin C was dissolved in 10 
mL of distilled water to a final concentration of 4 μg/mL. Cells were washed with PBS 1x and 
incubated with 1 mL of Mitomycin C and 49 mL of medium for 3 hours. The solution was 
removed and washed three times with PBS 1x. Right after 10 mL of Trypsin were added to 
detach cells from the plate. 10 mL of 3T3 media were added as soon as cells were detached. 
Volume was accumulated in a Falcon tube and centrifuged 4 minutes at 1000 rpm, and pellet 
was resuspended in 20 mL of media.  
A cell counter was used to count the number of cells. To do that, 20 mL of diluent and 100 μL 
of the sample were added into a special flask, the lid was closed, it was mixed well, and the 
flask was inserted inside the cell counter so that the probe was submerged in liquid.  
The next step was to centrifuge again at the same conditions and resuspend the pellet in 
Profreeze medium (90% Profreeze solution and 10% DMSO). The volume of Profreeze 
medium was calculated depending on the total number of cells. Each vial should have 1 mL 
and 6 x 106 cells, so the correspondent volume of Profreeze medium was added to a Falcon 
tube to resuspend the pellet carefully. Vials were stored overnight at -80°C inside Mr Frosty, 
and on the next day, vials were moved to the liquid nitrogen tank. 
 
3.3.1.5. FREEZING FIBROBLASTS AND KERATINOCYTES 
First steps were the same in splitting and freezing cells. Once the pellet was resuspended in the 
correct media, cells were counted with Cell counter using 20 mL of diluent and 100 µL of the 
sample.  
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After counting, cells were centrifuged again for 4 minutes at 1000 rpm and resuspended in 
Profreeze medium (90% Profreeze solution and 10% DMSO). The volume of Profreeze 
medium was calculated depending on the total number of cells, and 4 Million cells per vial 
were frozen. 1 mL of the sample was added to the vial and stored inside Mr Frosty overnight 
at -80°C freezer. On the next day, vials were stored in the liquid nitrogen tank.  
 
3.3.1.6. CALCIUM DIFFERENTIATION OF KERATINOCYTES 
Calcium concentrations are involved in keratinocytes control. For this reason, a calcium 
differentiation of these skin cells is carried out. Keratinocytes were growing in KGM media, 
and when they reached about 70-80% confluent, the differentiation was started (day 0). Cells 
from one of the dishes were washed with 3 mL of PBS 1x, 2 mL of Trypsin were added, and 
cells were incubated at 37°C until detached. Trypsin activity was stopped with 3 mL of trypsin 
inhibitor, and all volume was collected to a Falcon tube to be centrifuged at 1000 rpm for 4 
minutes. Pellet was resuspended in 3 mL of KGM media and number of cells was counted 
using a cell counter. Cells were centrifuged at the same condition and the supernatant obtained 
after centrifugation was discarded. Final pellet was stored at -20°C and used to extract RNA.  
3 mL of KGM with CaCl2 were added to the rest of the dishes to differentiate the keratinocytes. 
The protocol followed for every time point was the same than for the day 0. 
 
3.3.1.7. 3D FULL THICKNESS SKIN MODELLING 
Growing 3D full thickness skin models in cell culture is a complex process that involves the 
use of different cells and mediums, and special devices need to be combined in order to build 
the dermal end epidermal layers that allow the models to so closely resemble in vivo skin.  
Fibroblasts and basal keratinocytes without the support of feeder cells were grown until they 
were nearly confluent in 3T3 and KGM medium, respectively.  
The dermal layer, including fibroblasts and collagen, was prepared on top of a permeable 
membrane with a pore size of 3 µm. For that, fibroblasts were trypsinized on the day of skin 
modelling, counted and resuspended in serum (FBS) using 1.8 x 106 fibroblasts/6 well plate in 
1.8 mL serum.  Inserts were placed into each well of a deep 6 well plate before 2.5 mL of the 
following fibroblast/collagen mix was added. The collagen I matrix was prepared adding 1.8 
46 
 
mL of 10x HBSS to 14.4 mL of Pure Col Type 1 Bovine Collagen. While swirling this mixture, 
2M NaOH was added drop by drop to the bright yellow colour mix, until the pH indicator was 
back to pH 7, resulting in a red colour similar to the DMEM medium.  
The 6-well plate was incubated during 2 hours in a CO2-free incubator at 37°C. Under these 
conditions the matrix hardened to a pink gel. After the incubation, 2 mL of KGM medium were 
added from above to each matrix, and 14 mL were pipetted directly around each filter insert. 
The plate was then incubated for another 2 hours in an incubator at 37°C, 5% CO2 level and 
95% RH. After incubation, keratinocytes were then trypsinized, counted, and resuspended in 
KGM. The medium was removed from the top of the matrix and the keratinocyte-suspension 
was added onto the center of the matrix, with a density of 4-5 x 106 cells per mL of medium. 
Deep-well plates with filter inserts were incubated at 37°C, 5% CO2 level and 95% RH until 
day after.  
The following day, medium was removed from deep-well plate. This was followed by the 
“airlift”, where the medium is removed from the top of the cells. 10 mL of KCM were added 
to the deep-well plate of each model, and 3D skin models were transferred to the incubator. 
Medium was changed every other day. The final skin model was usually harvested on the day 
13 (Figure 11).  
 
Figure 11. Schematic representation of skin models. 
 
3D skin models were treated with labelled TGase1 (Alexa Fluor 488)/NG (Rhodamin) (10 μg 
nanogel loaded with 100 μg TGase1 in 1 mL PBS) every second day starting on the day 5 after 
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airlift. Before the treatment, medium was changed, and skin models were incubated for some 
time at 32°C to adjust them to the new conditions. 50 µL of the labelled complex were pipetted 
on top of the skin model, pipetting a droplet of 10 µL onto the centre of the model, followed 
by four other droplets around the first droplet. After application, each droplet was gently 
connected. Once the models were treated, they were exposed to a temperature gradient starting 
1 hour at 32°C, followed by 1 hour at 34°C, before normal incubation at 37°C, 5% CO2 level 
and 95% RH. 
 
3.3.1.8. PIG SKIN EXPLANT CULTURE 
Skin pig samples were collected from a Spanish abattoir. The sample was transported in 50 mL 
Falcon tube with cold transportation medium (TPM), and then it was washed once in the 
laboratory with Betaisodona solution for 2-3 minutes, followed by three wash steps in AA-PBS 
for 7 minutes.  
The sample was placed with epidermal side down in a petri dish, and some drops of AA-PBS 
were added until sample was lightly covered. The fat and hair were removed with some 
scissors, and the sample was then cut using a biopsy punch instrument. In parallel, filter-inserts 
were placed into a deep-6-well plate using the single-use plastic forceps. For organ culture, the 
skin samples cut with a biopsy punch were placed, with dermal side down, on the sterile filter-
inserts. 10 mL of PSE culture medium was added to the plate, from above (Figure 12).  
The skin culture was maintained at 37°C, 5% CO2 level and 95% RH and medium was changed 
every day.  
 
Figure 12. Schematic representation of pig skin explant. 
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3.3.2. ANALYSIS OF 2D KERATINOCYTES 
In order to study the location of the therapeutic protein complex TGase1/nanogel, porcine and 
human control keratinocytes were cultured and treated in a 2D monolayer.  
 
3.3.2.1. COVERSLIPS COATING 
Coverslips washed with ethanol were placed into p30 dishes. When the ethanol was evaporated, 
1mL of Poly-L-Lysine solution was added to each dish. After sitting for 10 minutes at room 
temperature, Poly-L-Lysine solution was removed, and dishes were washed three times with 
sterile water. When they were dried, they were irradiated with UV light for 45 minutes.  
Keratinocytes from pig and human control samples were plated on coverslips and grown in 
KGM medium. When the cells were about 70% confluent, they were treated with 5 μL of 2% 
labelled TGase1(Alexa Fluor 488)/NG (Rhodamin) complex (50 μg nanogel loaded with 0.5μg 
TGase1) in 1 mL of culture medium.  
 
3.3.2.2. IMMUNOCYTOCHEMISTRY 
After treatment, cells were washed once with PBS, and when the dishes were dried, 100% ice-
cold methanol was added. Cells were washed with washing buffer (1% BSA in PBS) twice 
after incubation overnight at -20°C, and permeabilized with 0.1% Triton X-100 in PBS for 10 
minutes at room temperature. Cells were then washed one with PBS/BSA and incubated for 2 
hours at room temperature with blocking solution (10% FBS, 1% BSA in PBS). Primary 
antibody was diluted in blocking solution and 400 μL of it were added to each dish. Next day, 
after incubation overnight at 4°C in a wet chamber, primary antibody was removed, cells were 
washed four times with washing buffer, and 400 μL of secondary antibody, previously diluted 
in blocking buffer, were added. Cells were incubated for 2 hours at room temperature in the 
dark. After that, cells were washed once with washing buffer, incubated with DAPI for 5 
minutes, washed three times with washing buffer, twice with PBS only, and once with distilled 
water. Fluromount Mounting Medium was used to preserve samples before visualisation under 
confocal microscope.  
All primary and secondary dilutions and antibodies details are shown in section 3.1. 
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3.3.3. HARVESTING AND ANALYSIS OF 3D SKIN MODELS 
After growth of control skin models, they were analysed. The harvest was carried out on the 
13th day after airlift, and then washed with PBS.  
 
3.3.3.1. PARAFFIN- AND CRYO-EMBEDDING  
Two biopsy punches were taken from the middle of the model with an 8mm punch for structure 
analysis and immune-histochemical stainings. The biopsies were then placed on top of a drop 
of PBS, which was on top of a petri-dish-lid, being cut in two halves using a scalpel. One of 
the halves was used for paraffin embedding while the other one was used for cryo-embedding.  
The sample designated for paraffin embedding was transferred into one CellSafe biopsy 
capsule, closed, and transferred to one histo-casette. The cassette was submerged in 10% 
formalin before fixation and dehydration in the tissue processing machine (Leica), where the 
following program was used (6h formalin) (Table 5).  
Table 5. Program used for paraffin embedding. 
Number of repeats Time (hours) Chemical 
1x 4 Formalin 
1x 2 Formalin 
1x 1.5 70% ethanol 
1x 1.5 80% ethanol 
1x 1.5 90% ethanol 
2x 1 100% ethanol 
2x 1.5 Xylene 
3x 1.5 Liquid 60°C paraffin 
 
When tissue processor finished, samples were embedded in first liquid paraffin, the sample was 
placed with the straight side of the half circle skin punch facing up on the liquid paraffin, and 
when cold, more liquid paraffin was added until sample was covered. Once hardened on a 
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cooling plate (4°C), samples were cut into 5 µm sections on a microtome, placed in microscope 
slides, and dried in a free-CO2 incubator for posterior haematoxylin and eosin (HE) stainings.  
The sample selected for cryo-embedding was taken to the cryotom (precooled -25°C). Some 
drops of NEG50 embedding medium were added on a stamp at the cryotom at -25°C, and let 
freeze until nearly hard. The biopsy half was placed with the straight side of the half circle skin 
punch facing up. After hardening of the embedding medium with the sample, some more drops 
of NEG50 embedding medium were added to cover the sample. Once hard, samples were 
stored at -80°C. 
 
3.3.3.2. HAEMATOXYLIN AND EOSIN STAININGS 
In order to evaluate the structure of our skin models, haematoxylin and eosin staining were 
performed on paraffin cuts. Haematoxylin stains the cellular nuclei dark purple, while eosin 
dyes the non-nuclear cells and structures pink/orange.  
The slides were placed into a staining rack and deparaffined with xylene during 40 minutes 
before they were submerged in the descending ethanol series (100%, 80% and 30% ethanol 
solution) for 4 minutes each. After that, slides were rinsed in tap water, and then placed in 
Haematoxylin for 8 minutes. Slides were rinsed in running tap water for 2 minutes, placed in 
Eosin for 4 minutes, and rinsed in tap water for 1 minute. Slides were then submerged in the 
ascending ethanol series (30%, 80%, 100% ethanol solution) for 4 minutes each before they 
were briefly submerged in xylene. Coverslips were then mounted on slides with Entellan 
Mounting Medium and dried in the fume hood for posterior analysis.  
 
3.3.3.3. IMMUNOHISTOCHEMISTRY 
Immunohistochemistry stainings were carried out for the study of specific expression markers 
on cryosections. 
Slides were transferred for 10 minutes into ice-cold acetone and then washed with PBS. 
Sections were blocked with blocking solution for 2 hours at room temperature. After the 
incubation, all liquid was dried, slides were placed in a wet chamber, specimens were circle 
with Dako pen, and 50 μL of primary antibody diluted in blocking solution were added. After 
incubation overnight at 4 °C, sections were washed three times with washing buffer (0.5% 
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Tween in PBS) and once with PBS. Secondary antibody was diluted in blocking solution, 50 
μL of which were added to slides, and they were incubated for 2 hours at room temperature in 
the dark, in the wet chamber. Slides were then washed with washing buffer and incubated with 
DAPI for 5 minutes. Sections were washed three times with washing buffer, twice with PBS 
only, and once with distilled water.  
All primary and secondary dilutions and antibodies details are shown in section 3.1. 
Sections were mounted with fluorescent protecting mounting medium before stainings were 
analysed in a fluorescence microscope. 
 
3.3.4. RNA EXTRACTION 
PureLink™ RNA Mini Kit (by Ambion) protocol was followed to extract RNA from pellets 
obtained from cultured cells. The purpose of the RNA extraction is the analysis of different 
genes in samples extracted from primary keratinocytes.  
60 mL of 100% ethanol were added to the Wash Buffer II when used for the first time. Lysis 
Buffer was prepared adding 10 μL of 2-mercaptoethanol for every 1 mL of Lysis Buffer to 
contain 1% of 2-mercaptoethanol.  
After the preparation of both buffers, protocol for ≤ 5 x 106 suspension cells were followed to 
carry out with binding, washing and elution. 0.3 or 0.6 mL of Lysis Buffer with 2-
mercaptoethanol (Table 6) were added to the sample according to the cell number. Suspension 
was vortex to disperse the pellet. 
Table 6. Required volume of Lysis Buffer. 
Cell number Lysis Buffer required for each sample (mL) 
≤ 1 x 106 0.3 
1 x 106 – 5 x 106 0.6 
5 x 106 – 5 x 107 0.6 for 5 x 106 cells (e.g., 1.2 per 1 x 107 cells) 
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Once cells were lysed, one volume of 70% ethanol was added to each volume of cell 
homogenate. Cells were mixed thoroughly by vortex, and 700 μL of them were transferred up 
to the spin cartridge with the collection tube. Each sample was centrifuged at 12000 x g for 15 
seconds at room temperature. The flow-through was discarded, and the spin cartridge was 
reinserted into the same collection tube. Each sample was centrifuged at the same conditions, 
and the flow-through was discarded again.  
700 μL of “Wash Buffer I” were added to the spin cartridge, and cells were centrifuged at 
12000 x g for 15 seconds at room temperature. The flow-through and the collection tube were 
discarded, and the spin cartridge was placed into a new collection tube.  
A DNase treatment was accomplished. 350 μL of “Wash Buffer I” were added to the spin 
cartridge containing the bound RNA and the spin was centrifuged at 12000 x g for 15 seconds 
at room temperature. The flow-through and the collection tube were discarded. The spin 
cartridge was inserted into a new collection tube.  
80 μL of PureLink® DNase mixture (Table 7) were added directly onto the surface of the spin 
cartridge membrane and incubated at room temperature for 15 minutes. 350 μL of “Wash 
Buffer I” was added to the spin cartridge. After centrifuging at 12000 x g for 15 seconds at 
room temperature, the flow-through and the collection tube were discarded. The spin cartridge 
was inserted into a new collection tube. 
Table 7. Composition of PureLink® DNase mixture. 
Component Volume (µL) 
10X DNase I Reaction Buffer 8 
Resuspended DNase (~ 3U/µL) 10 
RNase Free Water 62 
Final Volume 80 
 
500 μL of Wash Buffer II with ethanol were added to the spin cartridge and centrifuged at 
12000 x g for 15 seconds at room temperature. The flow-through was discarded. These steps 
were repeated once.  
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The spin cartridge was centrifuged at 12000 x g for 2 minutes to dry the membrane with bound 
RNA. The collection tube was discarded, and the spin cartridge was inserted into a recovery 
tube. 70 μL of RNase-free water were added to the centre of the spin cartridge and incubated 
for 1 minute at room temperature. The spin cartridge was centrifuged at 12000 x g for 2 minutes 
at room temperature to elute the RNA from the membrane into the recovery tube. The eluates 
were collected in a single tube (Figure 13). Purified RNA was stored and used to evaluate RNA 
quality and for cDNA synthesis. 
 
Figure 13. Schematic representation of RNA extraction. 
 
3.3.5. cDNA SYNTHESIS 
RNA concentration was estimated using "Nanodrop 2000/200c Spectrophotometer V1. 0 User 
Manual." (2009).  
The Nucleic Acid application was open in the NanoDrop Spectrophotometer. 1 μL of distilled 
water was loaded as a blank onto the lower measurement pedestal and the sampling arm was 
lowered. “Blank” was clicked to measure and store the reference spectrum. When the 
measurement was completed, a dry, lint-free lab wipe was used to remove the buffer from both 
the top and bottom measurement surfaces. An aliquot of the buffer was pipetted onto the 
pedestal, the arm was lowered and “Measure” was clicked. The surfaces were cleaned.  
After the blank measurement, 1 μL of every sample was pipetted directly onto the measurement 
pedestal. The sampling arm was lowered, and a spectral measurement was initiated using the 
software on the PC. When the measurement was completed, the sampling arm was raised, and 
the sample was wiped from both the upper and lower pedestals.  
500 ng of RNA were used to perform cDNA-synthesis with the High-Capacity RNA-to-cDNA 
TM Kit. Each reaction contained 10 μL of Reverse Transcriptase buffer mix (2x), 1 μL of 
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Reverse Transcriptase enzyme mix (20x) as well as the RNA and was toped up with 
RNAse/DNAse free water to a total volume of 20 μL. The reaction was put for 1 hour at 37°C 
and 5 minutes at 95°C to complete cDNA-synthesis in the PCR machine/Thermocycler. cDNA 
was diluted afterwards 1:10 in RNAse/DNAse free water and stored for using to analyse the 
different genes through qRT-PCR. 
 
3.3.6. TaqMan REAL TIME PCR (qRT-PCR) 
qRT-PCR was carried out for analysing different primers and housekeeping genes on 
keratinocyte samples. A reaction mix for the Master Mix plus the assay primer and probe mix 
was prepared. Furthermore, a sample mix for each cDNA was prepared as well. 
Table 8. Quantities of Master Mix, primer, cDNA and distilled water for every plate. 
Reaction Component 1x reaction 
25x reaction (for 24 
wells on one plate) 
Reaction 
Mix 
Master Mix 5 µL 125 µL 
Assay primer and probe mix 0.5 µL 12.5 µL 
Sample 
Mix 
cDNA diluted 1 µL 10 µL 
Distilled water 3.5 µL 35 µL 
 
A fresh PCR fast plate was put on ice and 5.5 μL of the reaction mix were pipetted into the 
correct well until the plate was full. When it was ready 4.5 μL of sample mix were added to 
each row (Figure 14). Then the plate was covered with an adhesive film and centrifuged. The 
plate was put into the StepOnePlusTM Real-Time PCR System and the template was adjusted 
to the correct samples to be run and to analyse the results. 
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Figure 14. Drawing of the plate with the samples and primers. 
 
The StepOneTM Software included with the StepOnePlusTM Real-Time PCR System runs on 
the Windows® XP operating system and provides instrument control, data collection, and data 
analysis capabilities. 
Table 9. Cycling conditions to run RT-PCR. 
StepOnePlusTM Instrument: 96-well Real-Time PCR 
Type of experiment: Quantitation 
Quantiation method: Comparative CT (ΔΔCT) 
Reagents to detect the target sequence: TaqMan® Reagents 
Ram speed: Fast (~ 40 minutes to complete a run) 
Run method: cDNA 
Run method:  Reaction volume per well: 10 µL 
Holding stage: 25oC → 95oC (20 seconds) Step 1 
Cycling Stage: 40 cycles: 95 oC (1 second) Step 1 
                                          60 oC (20 seconds) Step 2 
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3.3.7. STATISTICAL ANALYSIS 
Mean and standard error were calculated for each data set from duplicates. Statistical analysis 
was performed using Independent T-test analysis in SPSS (SPSS Inc., Chicago, IL, U.S.A.).  
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4. RESULTS 
4.1. GENE EXPRESSION IN DIFFERENTIATED AND NON-DIFFERENTIATED 
PRIMARY KERATINOCYTES. 
Calcium has been showed to induce keratinocyte differentiation, which is associated with the 
moving of keratinocytes through the strata of the epidermis to form the skin barrier.  
Because calcium is considered a main factor in the regulation of keratinocyte differentiation, 
we have studied how different genes act in keratinocytes differentiating with calcium induction.  
Primary human and pig normal epidermal keratinocytes (hKC15 and pKC1) were grown in 
KGM medium and differentiated with calcium induction when cells were about 80% confluent, 
following the protocol described in section 3.3.1.6. Three time points, which are day 0, day 7, 
and day 14, were carried out in the calcium differentiation, RNA was extracted from the 
differentiated cells cultured in the laboratory, and cDNA was synthesized and analysed through 
qRT-PCR. Three genes and one housekeeper were used for the analysis. Those genes were 
TGM1, ALOXE3 and ALOX12B, and the housekeeping gene was GAPDH. These results were 
also compared to an ARCI patient with mutation in TGM1, which cells were grown in a 2D 
monolayer, and treated with TGase1.  
              
Figure 15. Gene expresion in differentiated primary keratinocytes. RNA was extracted 
from keratinocytes derived from human and pig tissue, differentiated with 1.2 mM and 1 mM 
calcium chloride, respectively. qRT-PCR was performed for specific markers. Resulting CT 
values were normalized using houskeeping gene GAPDH and to the respective control sample 
(non differentiated primary keratinocytes) which expression values are 1. Graphics show the 
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relative gene expression (ratio) of specific genes for human (A) and porcine (B) primary 
keratinocytes. Duplicates from the same donor were used for the analysis. Errror bars indicate 
standard deviation. 
 
 
Figure 16. Gene expresion in basal primary keratinocytes. RNA extraction was carried out 
from keratinocytes derived from an ARCI patient with mutation in TGM1. Cells were treated 
with TGase1 and analysed by qRT-PCR. CT values, given as results of the analysis, were 
normalized using GAPDH as housekeeping gene and to an untreated control sample (non 
differentiated primary keratinocytes), which expression values are 1. Graphic shows the 
relative gene expression (ratio) of specific genes for treated and untreated primary 
keratinocytes. Duplicates from the same donor were used for this analysis. Error bars indicate 
standar deviation.  
 
CT values were obtained by the StepOne
TM Software included with the StepOnePlusTM RT-PCR 
system, where CT is defined as the number of cycles needed for the fluorescence to reach a 
specific threshold level of detection and is inversely correlated with the amount of template 
nucleic acid present in the reaction. Replicates from the same donor were used, so an average 
with CT values was calculated to determinate the difference between the CT value of the target 
gene and the CT value of the housekeeper (reference gene) (value called delta CT or ΔCT). The 
ΔCT value of the test sample minus the ΔCT value of the control sample, which are non 
differentiated primary keratinocytes gave as result what is called ΔΔCT, the value used to 
calculate the ratio or the relative gene expression (2-ΔΔCT). To summarise: ΔΔCT  = ΔCT test sample 
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- ΔCT control sample, where ΔCT = CT target gene - CT reference gene. The relative gene expression was the 
one used to analyse the results shown in the figures 15 and 16.  
As it can been seen in Figure 15, despite all markers present a higher expression when human 
(A) and pig (B) keratinocytes (A) are not differentiated (day 0), except when analysing TGM1 
(Figure 15B), where an increase in the differentiation can be seen, TGM1 increases with the 
keratinocyte differentiation in both cell lines. However, the opposite occurs with ALOX12B and 
ALOXE3, as their expression decreases in the late stages of the differentiation.  
In Figure 16, where keratinocytes from an ARCI patient with mutation in TGM1 were used for 
the study, a slightly increase of expression can be observed for TGM1 and ALOXE3 when cells 
were treated with TGase1, while expression was higher for untreated keratinocytes than treated 
for ALOX12B.  
 
4.2. 3D SKIN MODELS CHARACTERIZATION 
3D skin models of human skin are used in biomedical and pharmacological research for drug 
development and for the study of skin disease, being an alternative method to animal 
experimentation (Mathes, Ruffner, and Graf-Hausner, 2014). 3D full thickness skin models are 
constructed by a collagen and fibroblasts matrix, which is equivalent to the dermis, with 
keratinocytes growing on it to mimic the epidermis. These models can resemble most of the 
characteristics of the native human skin and we have used them to test the effect of the 
therapeutic TGase1/NG complex.  
To accomplish this, fibroblasts and keratinocytes derived from healthy human donors were 
used to construct control 3D skin models. Models were cultured for 13 days and then 
characterized regarding structure and protein expression.  
Furthermore, we compared those models from healthy human donors with diseased skin 
models. The fibroblasts and keratinocytes used for the diseased skin models were derived from 
ARCI patients with mutations in TGM1, and they were cultured for 13 days by a colleague 
from our research group.  
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4.2.1. EVALUATION OF SKIN STRUCTURE IN 3D SKIN MODELS 
To evaluate the structure of 3D skin models, H&E staining (as explained in chapter 3.3.3.2.) 
was carried out on control and diseased models (Figure 17).  
After culturing the 3D skin models for 13 days, two biopsy punches were taken from their 
middle, processed in the tissue processing machine, and paraffin-embedded (as mentioned in 
paragraph 3.3.3.1.). Samples were sectioned with a microtome for evaluation of their structure 
by H&E staining.  
 
Figure 17. Characterization of untreated and treated control, and ARCI-patient derived 
3D skin models (day 13). H&E staining shows structure of models by staining nuclei in dark 
purple, and corneal layer in pink. Bars 100 µm.  
 
H&E staining shows a well-established structure in all untreated and treated control and 
diseased skin models. Untreated and treated control models present a multi-layered thick 
epidermis with nuclei in the stratum granulosum, while TGM1-patient skin models manifest an 
epidermis that has become flatter. The number of nuclei in the stratum granulosum is also lower 
in the case of diseased models.  
 
4.2.2. CHALLENGES IN 3D SKIN MODEL CONSTRUCTION 
The construction of 3D skin models is a complex and sensitive process, and the generation of 
good skin models is challenging. The main factor that generates changes in the skin models are 
the keratinocytes. Well-structured models are produced when the correct number of basal 
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keratinocytes is used, and when those keratinocytes are not starting to look differentiated, 
which can happen when high passages are used. 
Other factor to take in consideration is the Pure Col Type 1 Bovine Collagen used and possible 
changes in the humidity in the incubators. After preparing matrix and incubating in the CO2-
free incubator, a non-hardened matrix was sometimes produced, affecting the quality of the 
skin model produced.  
Therefore, only well-structured models are suitable to reproduce skin in vitro and will be used 
for experiments.  
 
4.3. APPLICATION OF TGase1/NG COMPLEX IN CELLS GROWN ON A 2D 
MONOLAYER 
To assess the cellular distribution of TGase1 and the NG in primary cells, isolated keratinocytes 
from porcine and human healthy controls were cultured on a 2D monolayer. Cells were cultured 
on Poly-L-Lysine-treated coverslips inserted in culture dishes and fed with KGM medium. 
When cells were about 70% confluent, 5 μL of 2% labelled TGase1(Alexa Fluor 488)/NG 
(Rhodamin) complex (50 μg nanogel loaded with 1 μg TGase1) were added in 1 mL of culture 
medium. Three conditions were carried out for this experiment: untreated (UT) cells, cells 
treated for 3 hours at 37oC, and cells treated for 24 hours at 37oC. After incubation times, cells 
were fixed following the protocol described in section 3.3.2.2., stained with 4 specific 
antibodies (anti E-cadherin, anti EEA1, anti GM130, and LysoTracker Deep Red), 
counterstained with DAPI, and analysed by confocal microscopy (Figure 18-25). As 
LysoTracker Deep Red is a fluorescent dye, secondary antibody was not needed for its stain, 
and its application was performed in live cells after TGase1/NG treatment and before fixation. 
Specifically, anti E-cadherin detects the membrane, anti EEA1 shows the endoplasmic 
reticulum, anti GM130 is specific for Golgi, and LysoTracker Deep Red tracks lysosomes. As 
TGase1 and the nanogel are labelled, this method is an effective way to check their progress in 
keratinocytes.  
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Figure 18. Anti E-cadherin staining when application of labelled TGase1/NG complex in 
basal, control human keratinocytes. Untreated and treated cells (after 3 hours or 24 hours of 
incubation with 2% TGase1/NG complex) were stained with anti E-cadherin antibody, a 
marker specific for membrane, using Alexa Fluor® 633 (red) as secondary antibody. TGase1 
was labelled with Alexa Fluor® 488 (green) and the nanogel was labelled with Rhodamin (red, 
pseudo-colored orange). Nuclear counterstaining was performed with DAPI (blue). Bars 20 
µm.  
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Figure 19. Anti EEA1 staining when application of labelled TGase1/NG in basal, control 
human keratinocytes. Cells were stained with anti EEA1 antibody, a marker specific for 
endoplasmic reticulum, using Alexa Fluor® 633 (red) as secondary antibody. TGase1 was 
labelled with Alexa Fluor® 488 (green) and the nanogel was labelled with Rhodamin (red, 
pseudo-colred orange). DAPI (blue) was used for nuclear staining. Bars 20 µm. 
 
Figure 20. Anti GM130 staining when application of labelled TGase1/NG in basal, control 
human keratinocytes. Untreated cells, as well as treated, were stained with anti GM130 
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antibody, a specific marker for Golgi, using Alexa Fluor® 633 (red) as secondary antibody. 
The TGase1/NG complex was labelled with Alexa Fluor® 488 (green) for TGase1 and with 
Rhodamin (red, pseudo-colred orange) for the nanogel. Nuclear counterstaining was performed 
with DAPI (blue). Bars 20 µm. 
 
Figure 21. LysoTracker deep red staining when application of labelled TGase1/NG in 
basal, control human keratinocytes. Untreated and treated cells were stained with 
lysoTracker Deep Red (red), a specific dye for lysosomes, before fixation of the cells and after 
treatment with the TGase1/NG complex, labelled with Alexa Fluor® 488 (green) for TGase1 
and with Rhodamin (red, pseudo-colred orange) for the nanogel. To stain the nuclei, DAPI 
(blue) was used. Bars 20 µm. 
 
After culture of untreated and treated cells cultured in a 2D monolayer and staining with 
different antibodies specific for some organelles, analysis was carried out with confocal 
microscope. TGase1 enters the keratinocytes, as expected, and the nanogel also enters the 
cytoplasm. When comparing the intensity of TGase1 and nanogel signals, the signal for the 
complex is stronger when the treatment was carried out for 24 hours. Upon 3 hours treatment, 
TGase1/NG complex is located around the nuclei, and in the cytoplasm and membrane. 
Subsequently, when treatment is carried out for 24 hours, TGase1/NG complex seems to stay 
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around the nuclei, cytoplasm and membrane, therefore the complex does not seem to enter the 
nuclei any time. 
Senescent cell appearance can be observed at 24 hours for each antibody. In addition, 
keratinocytes are in senescence when no treatment was used for the lysotracker staining. An 
atypical dystribution of lysotracker staining is also seen, and anti E-cadherin staining is not 
very accurate, as not only the membrane is stained. Nuclei appear stained when anti E-cadherin 
was used. 
Due to the fact that the complex is a 2% TGase1 solution in the nanogel, the fluorescent signal 
of the rhodamine always appeared stronger that the Alexa Fluor® 488 signal.  
 
As pigs share many physiological and anatomical similarities with humans, like a structurally 
similar skin, we compare human and pig keratinocytes from healthy controls, grown and treated 
with the TGase1/NG complex in the same conditions.  
 
Figure 22. Anti E-cadherin staining when application of labelled TGase1/NG complex in 
basal, control porcine keratinocytes. Untreated and treated cells were stained with anti E-
cadherin antibody, using Alexa Fluor® 633 (red) as secondary antibody. TGase1, part of the 
treatment complex, was labelled with Alexa Fluor® 488 (green), and the nanogel was labelled 
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with Rhodamin (red, pseudo-colred orange). To stain the nuclei, DAPI (blue) was used. Bars 
20 µm. 
 
 
Figure 23. Anti EEA1 staining when application of labelled TGase1/NG complex in basal, 
control porcine keratinocytes. Untreated cells, and cells treated with 2% labelled TGase1/NG 
complex, were stained with anti EEA1 antibody using Alexa Fluor® 633 (red) as secondary 
antibody. TGase1 was labelled with Alexa Fluor® 488 (green), while the nanogel was labelled 
with Rhodamin (red, pseudo-colred orange). Nuclear counterstaining was performed with 
DAPI (blue). Bars 20 µm. 
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Figure 24. Anti GM130 staining when application of labelled TGase1/NG complex in 
basal, control porcine keratinocytes. Cells were stained with anti GM130 primary antibody, 
using the secondary antibody Alexa Fluor® 633 (red). TGase1 was labelled with Alexa Fluor® 
488 (green) and the nanogel was labelled with Rhodamin (red, pseudo-colred orange). DAPI 
was used to counterstain the nuclei. Bars 20 µm. 
 
Figure 25. LysoTracker deep red staining when application of labelled TGase1/NG 
complex in basal, control porcine keratinocytes. Keratinocytes were stained with 
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LysoTracker Deep Red dye (red) before cells were fixed, and after application of TGase1/NG 
complex, which was labelled with Alexa Fluor® 488 (green) for the TGase1, and Rhodamin 
(red, pseudo-colred orange) for the nanogel. Nuclei were stained with DAPI (blue). Bars 20 
µm.  
 
When using porcine keratinocytes, our TGase1/NG complex enter the keratinocytes going both 
our protein and the nanogel to the cytoplasm. After 24 hours, the signals for the complex are 
stronger than when cells were incubated for 3 hours with the treatment. As in human 
keratinocytes, TGase1/NG complex does not seem to enter the nuclei when 3 hours treatment 
or 24 hours treatment, being located in the cytoplasm and membrane.  
In this case, senescent cell appearance is not observed in any condition. As in human primary 
keratinocytes, an atypical dystribution of lysotracker staining is seen, and anti E-cadherin is 
stained in both membrane and nuclei.  
 
4.4. CHARACTERIZATION OF PIG SKIN EXPLANTS 
Skin explants are models close to in vivo skin, and they are made by keratinocytes, 
melanocytes, Langerhans cells, fibroblasts, collagen and glycosaminoglycans, while the 3D 
skin models are only formed by keratinocytes and fibroblasts. Also, skin explants can be used 
immediately, there is no need of time to prepare them. Because human skin in large quantities 
is not easy to obtain, we thought that porcine skin could be an alternative to test our therapeutic 
TGase 1 protein and see how it behaves in in vivo circumstances.  
Several skin samples from different pigs were received from a Spanish abattoir and cultured in 
the laboratory as skin explants. Medium was changed every day and incubated at 37oC in an 
atmosphere of 95% air and 5%CO2. 
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Figure 26. Pig skin explants. 
 
Pig skin explants (Figure 26) were cultured for 13 days, but their culture has been a challenge. 
In first place, tissue samples must be fresh. No changes in skin explants are in fact observed 
when skin samples have been obtained subsequently treatment and processes (e.g. removing 
hair) run before slaughtering the animal. Those and old samples cannot be used for the 
experiments due to cells being already dead. 
Consequently, obtaining the skin samples turned to be a great challenge that influenced our 
study. No local abattoirs in fact agreed to provide us the requested samples.  In order to 
overcome this problem, we contacted a slaughterhouse in Galaroza (Spain), who agreed to 
supply us the fresh (alive) pig skin samples. However, the career used and the shipping time, 
mainly due to the hot temperature and holidays season, turned out to be inadequate. Once 
received in fact, explants resulted to be contaminated after 2 days of being in culture. 
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5. DISCUSSION 
ARCI is a diverse group of diseases that share some characteristics such as autosomal recessive 
pattern of inheritance, newborns presenting collodion membrane, and overlap in causative gene 
(Oji et al., 2010). ARCI is a rare disease, therefore less than 2 in 100000 of the population 
present the disease. Around 7000 rare diseases are known, and 80% are genetic. Rare diseases 
are often misdiagnosed or diagnosed with a major delay, however The World Health 
Organization (WHO) has expressed concern about them (Puiu and Dan, 2010). 
In the case of ARCI, eleven genes have been associated with different ARCI phenotypes, being 
mutations in TGM1 the most common cause of ARCI. TGM1 encodes for TGase1, that 
catalyses the Nε-(γ-glutamyl) lysine crosslinking of precursor proteins, such as loricrin or 
involucrin, during the formation of the cytoplasmic layer of the cornified cell envelope, 
structure important for the skin’s barrier function. Subsequently, defects in the cornified cell 
envelope in the epidermis and altered expression of these proteins are shown in patients with 
ARCI, mostly due to TGM1 mutations (Herman et al., 2009). 
Unfortunately, the only current available treatment for this skin disease is symptomatic, 
providing symptomatic relief to the patient, but not eliminating the symptoms. Therefore, a 
causative treatment has to be developed. Witting et al. (2015) synthetized a thermoresponsive 
PNIPAM-dPG nanogel for cutaneous protein TGase1 delivery in skin models, a personalized 
TGase1 substitution therapy, to restore the skin barrier function in ARCI patients with 
mutations in TGM1.  
With this project, we aimed to better understand the fate of the PNIPAM-dPG nanogel and the 
loaded TGase1 protein when they are delivered in the skin.  In parallel, these studies have been 
also carried out with porcine skin samples due to its similarities with human skin.  
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5.1. COMPARISON OF HUMAN AND PIG KERATINOCYTES GROWTH 
CONDITIONS 
Comparing the cell lines used, human and porcine keratinocytes were isolated following the 
same protocol and cultured in the same culture medium (KGM medium when cultured without 
feeder cells, and KCM medium when cultured on feeders) and same conditions. After splitting, 
at first day, only a few colonies of porcine keratinocytes were observed. It was not until day 6-
7 when proliferating keratinocytes were observed, as it was previously seen in Ponce’s research 
(2017). Porcine keratinocytes were then taking more time than human keratinocytes in 
replicating. We also observed that porcine keratinocytes were growing nicer and faster when 
on feeder cells, as sometimes, when growing them without the support of feeders, they started 
to look differentiated. This could be due to the medium used to culture them. Regarding the 
morphology (figures not shown), no differences between human and porcine keratinocytes 
were observed. 
In future studies, other keratinocytes growth medium could be tested, as EpiLife or KGM Gold, 
to evaluate if the proliferation of keratinocytes extracted from porcine skin samples is faster 
and their morphology is nicer. Concerning morphology, human and porcine keratinocytes look 
very similar. No differences can be appreciated.  
 
5.2. TGase1 IS EXPRESSED ON RNA LEVEL IN 2D KERATINOCYTES 
We aimed to examine the expression of three genes associated with ARCI when primary 
keratinocytes are differentiated and when they are non-differentiated in vitro. Also, we wanted 
to analyse those genes in samples from ARCI-patients with TGM1 mutation. Skin sample of 
the patient was extracted by upper arm biopsy. This patient, a 43 years old male, had disease 
causing mutations in TGM1 leading to lamellar ichthyosis. He features a homozygous mutation 
in exon 3, c.428G>A corresponding to p.(Arg143His).  
To accomplish this, different cell lines (human and porcine primary keratinocytes) were grown 
and when they were about 70% confluent, differentiation was induced by calcium application. 
After several days of culture, pellet was collected to extract RNA, for the posterior synthesis 
of cDNA to finally perform the qRT-PCR through which we will be able to analyse the relative 
gene expression. 
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The three genes used to study the gene expression were TGM1, ALOX12B and ALOXE3. TGM1 
is a member of the transglutaminase family and codes for the TGase 1 enzyme, which catalyses 
the crosslinking between polypeptides. TGase1 is involved in the assembly of the cornified 
envelope at the cell periphery of corneocytes, and it is the most common cause of ARCI 
(Haneda et al., 2016). ALOX12B and ALOXE3 are lipoxygenases genes that encode two LOX 
proteins, 12R-LOX and eLOX3, which are involved in the conversion of linoleoyl ceramide in 
the cornified envelope, into cornified envelope, which plays an important role in the 
maintenance of epidermal barrier formation (Krieg and Fürstenberger, 2014; Mashima and 
Okuyama, 2015). Genetic failures of these processes lead to ARCI (Eckl et al., 2009).  
Target gene expression was calculated relatively to a stably expressed gene, which should be 
uniformly expressed during all experimental conditions. The housekeeping gene used was 
GAPDH, which is a highly expressed multifunctional protein that participated in diverse 
activities as glycolysis, transcriptional and posttranscriptional gene regulation, maintenance of 
DNA integrity, vesicular transport, and chromatin structure (Khan et al., 2013).  
Quantitative real time PCR shows an increase in the gene expression of TGM1 in the late stages 
of the keratinocyte differentiation for both cell lines, human and porcine controls (Figure 15A-
B). In figure 15A, a high TGM1 expression in day 0 can be seen, that decreases when 
keratinocytes start the differentiation (day 7) and that increases at later stages (day 14). In figure 
15B, TGM1 expression is very low when differentiation was not started (day 0), expression 
that increases during the differentiation (TGM1 expression in day 7 is lower comparing to 
expression in day 14). 
The expression of TGase1 in the differentiation was expected, as differentiation requires the 
expression of this protein for the crosslinking of protein through the formation of covalent 
isopeptide bonds. Recent studies have also proved the variation of TGM1 expression in 
keratinocyte differentiation. Enomoto et al. (2003) indicated a high gene expression of TGM1 
after the initiation of differentiation in primary human keratinocytes, compared with its 
expression before the differentiation. Yamane et al. (2016) showed that the activity of TGase1 
at the early stages of the differentiation was maintained at a similar level and increased in 
differentiating keratinocytes together with other catalysed substrates.  
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A reduction in the gene expression of ALOX12B and ALOXE3 during the differentiation can 
be observed (Figure 15 A-B). Our findings suggest, for both human and porcine differentiated 
keratinocytes, a decrease of ALOX12B expression until day 7 (early stage of the 
differentiation), that keeps decreasing at day 14 (later stage).  
In 2009, Kim et al. demonstrated, in primary keratinocytes isolated from new-born mice, that 
the expression of Alox12b is directly induced by ΔNp63, contributing to epidermal barrier 
formation. This induction is dependent on intact p63 binding sites in the Alox12 promoter and 
only occurs in differentiating keratinocytes (Kim et al., 2009). The fact that ΔNp63 induces 
ALOX12B can explain our results, as ΔNp63 is mostly involved at the beginning of the 
differentiation (Koh et al. 2015). In contrast with our results, it is also suggested that ALOX12B 
and ALOXE3 are expressed in the terminal differentiation of keratinocytes. However, it is still 
unclear, if the role of LOX-dependent pathway is structural, or if it is involved in signalling, in 
epidermal differentiation (Jobard et al., 2002; Moran et al., 2007).  
ALOX12B and ALOXE3 have also been seen to participate in the keratinocyte differentiation 
by the formation of products which act in the differentiation. Therefore, they are involved in 
the regulation of proliferation and differentiation of keratinocytes. This is also supported by 
studies showing that inactivating mutations in these genes are linked to the development of 
ARCI (Yu et al., 2003; Epp et al., 2007). 
 
When looking at the patient samples (Figure 16), a higher ALOX12B expression can be seen 
when patient keratinocytes were not treated, comparing to treated cells, while ALOXE3 
expression is increased in treated patient cells than in untreated. A significant reduction of 
TGM1 expression on the RNA level can be seen, as well as of the other genes. This decrease 
of the gene expression is also observed when the patient is treated with the TGase1/NG 
complex. This patient is known to carry a homozygous mutation in exon 3 leading to nonsense 
mediated decay meaning that he does not express the protein at all. The fact of that the 
therapeutic complex did not increase the expression of TGM1, could be due to the application 
itself topically, so we are not expected to see a direct change on the TGM1 expression because 
it is still mutated. We would expect TGM1 expression to go up if would have done gene editing 
and corrected the mutation, other strategy for therapeutic development that has been done for 
epidermolysis bullosa (Hainzl et al., 2017). 
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These analyses therefore confirm the expression of TGM1 on RNA level in control and 
diseased 2D keratinocytes. Also, the use of primary keratinocytes isolated from biopsies of 
patients is a very valuable model for investigating proteins and genes involved in epidermal 
differentiation, and they contribute to the basic knowledge of the mechanism of different skin 
diseases.  
It has also been seen that some of these markers are induced by other proteins. As previously 
mentioned, the expression of ALOX12B is directly induced by ΔNp63, contributing to 
epidermal barrier formation (Kim et al., 2000). In addition, TGM1 expression can be induced 
by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is involved in the 
initiation of keratinocyte differentiation by p63. p63, which is a reliable keratinocyte stem cell 
marker, plays a major role in ectodermal development, in the maintenance of a basal cell 
population and in the terminal differentiation of stratified epithelia, where it can also induce 
the expression of involucrin, Reis-Filho et al., 2002; Koster, 2010; Wu et al., 2011). 
Furthermore, mutations in the genes causing ARCI, like ALOX12B or ALOXE3, can also 
influence the expression of some differentiation markers such as filaggrin (Eckl et al., 2011).  
In future studies, it would be also interesting for our research to analyse the gene expression of 
different differentiation markers of the skin, such as involucrin, filaggrin, and p63 and its two 
main isoforms (ΔNp63 and Tap63) in undifferentiated and differentiated cells grown in 2D 
monolayer, but also in treated and untreated skin cells for a better comprehension of them and 
of the TGase1/NG complex treatment.  
It has also to be mentioned that no literature concerning studies with transglutaminase 1 of 
porcine skin has been found, so that we assumed that TGase1 is very similar in pig and human 
skin, as TGM1 in porcine skin is highly homologous to TGM1 in human skin. In a first instance 
we analysed gene expression with a human specific TGM1 TaqMan assay (assay ID 
Hs01070310_m1, designed by Applied Biosystems), obtaining undetermined values when 
cDNA from pig cell line was used. Therefore, as predesigned pig assays did not seem to be 
available, one specific for human but similar to pig sequence was used (assay ID 
Hs00165929_m1, designed by Applied Biosystems). Subsequently, with this second TaqMan 
assay for human TGM1, gene expression values were obtained for the pig samples, but not for 
the human samples, so that for the posterior analysis of the gene expression and obtaining the 
results shown in Figure 15(A-B), a combination of both assays was made.  
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To compare human and porcine samples, a series of independent t tests was run to compare the 
different conditions of TGM1 and ALOX12B expression at days 0, 7 and 14. T test showed no 
statistically significant differences (P value > 0.05) when comparing both genes between the 
two species, and at the different time points. However, this analysis is just preliminary, as only 
duplicates were run for each gene.  
Despite the statistical analysis did not show any significant differences, when looking at the 
qPCR data (figures 15A-B), a difference in the ratio at day 0 for ALOX12B may be observed. 
This is unexpected, and it might be due to the control used for the qPCR analysis, or the 
TaqMan assay used, as it could be specific only for human. Therefore, further replicates are 
needed to run a more powerful statistical analysis and eliminate any calibration error, in order 
to better clarify and understand the similarities of differences between these genes in human 
and porcine samples. 
Large error bars can be observed in figures 15A and 16 for some of the samples (TGM1 at day 
14 in human keratinocytes differentiation, and TGM1 in treated sample), which can be due to 
errors when pipetting to prepare the qPCR experiment.  
In further studies, new suitable TaqMan assays for both cell lines, porcine and human primary 
keratinocytes, should be found for a better understanding of how TGM1 is expressed in porcine 
cells. Furthermore, undetermined values were obtained when using a human specific ALOXE3 
TaqMan assay (assay ID Hs00222134_m1, designed by Applied Biosystems), therefore new 
TaqMan probes suitable for porcine cells would be helpful for future experiments. Also, a 
comparison between the studied samples (differentiated cells) to other calibrator samples used 
for the analysis of the qPCR data will be used in future experiments. In addition, more time 
points will be carried out in the differentiation to further understand the role of the genes in the 
differentiation, and in the different species.   
 
5.3. CONTROL AND DISEASED 3D SKIN MODELS ARE GOOD SYSTEMS 
TO TEST PROTEIN SUBSTITUTION 
After proved that TGM1 is expressed in both porcine and human primary keratinocytes, we 
constructed human control 3D skin models and evaluated their characteristics through H&E 
and immunohistochemistry staining for epidermal markers. Also, this evaluation was carried 
out on human diseased 3D skin models previously made by a colleague from our research 
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group. The diseased 3D skin models were built with keratinocytes and fibroblasts from an 
ARCI patient with mutation in TGM1.  
H&E staining seems to show hyperkeratosis in the control model, which is not seen in the 
treated control, where we would not expect a major difference; the untreated patient model 
shows a perfect epidermis, while the treated patient shows some hypoplasia and a mild 
hyperkeratosis. The treated models are as expected, while the non-treated models are not as 
expected. These differences can be due to the age of the keratinocytes used for the models, as 
models can differ from each other if keratinocytes are in high passages or if they start to 
differentiate.  
Despite H&E staining shows that the morphology of the diseased model is slightly different to 
the morphology of the control skin model, assessment of epidermal markers like K14 and K10 
in immunohistochemistry stainings carried out by one of our colleagues, reveals that their 
expression was optima as they were correctly distributed through all the models. Therefore, the 
keratinocyte differentiation was in accordance with what it was expected, as K14 expression 
was present in the basal layer, and K10 in the supra basal layer. When comparing with human 
skin, the expression for some markers like K14 was less well-defined for the 3D skin 
equivalents.  
Keratins are the principal components of the intermediate filament cytoskeleton in epithelial 
cells. K14 is expressed in the mitotically active basal cells, but when cells enter the terminal 
differentiation, it is substituted by K10 (Santos et al., 2002). Barker et al. (2004) showed the 
expression patterns of K10 in all supra basal layers. Similar results were obtained by Jung et 
al. (2014), who presented K14 expression in the basal layer, and K10 expression in the supra 
basal keratinocyte layer of the KeraSkinTM-VM model, showing an extended staining for these 
keratins through all layers. Ojeh et al. (2017) also revealed K14 expression in the basal layer 
of the epidermis, while K10 expression was in the supra basal layer. 
When staining with TGase1 antibody, a clear difference is shown comparing control and 
diseased skin models. As expected, the expression of the TGase1 in diseased models was lower 
than in the control equivalents, which expressed an active membrane-bound TGase1 in the 
upper layers of the epidermis. These differences are due to TGM1 mutation in the diseased skin 
models, which means that because TGM1 is mutated, a lower or no expression is going to be 
shown after stainings. This was also observed by Aufenvenne et al.’s research (2013), who 
showed a defeat of activity stainings in models generated from TGase1-deficient skin. Akiyama 
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et al. (2010) carried out studies with 4 patients with lamellar ichthyosis caused by TGM1. Only 
the two patients with missense mutations and mild hyperkeratosis showed TGase1 staining and 
activity. 
In conclusion, 3D skin models were successfully constructed and characterised by histology, 
and gene expression and for their functional barrier (by a colleague from the group, results not 
shown) to demonstrate the equivalency to in vivo conditions.  
However, it has to be taken in consideration that the construction of 3D skin models is 
challenging. One of the main issues has been the undesirable differentiation of keratinocytes 
when cultured in 2D monolayers without feeder cells before transferring them onto the 
fibroblast/collagen matrix for building 3D skin models. This influenced the structure of the 
models, because when keratinocytes are not basal keratinocytes, the model does not grow as 
desirable. This was shown by Carlson et al. (2008), whose group carried out the development 
of 3D human skin equivalents of normal and diseased skin. Carlson et al. (2008) also indicated 
that despite nearly all keratinocytes seeded onto the skin model attached to the connective 
tissue substrate, only those cells that were replicating grew after seeding. Keratinocytes that 
were differentiating also adhered to the connective tissue substrate, but they did not proliferate 
to form the stratified human skin equivalent. For this reason, is important to work with low 
passage keratinocytes, as most of the keratinocytes will grow as basal cells and with a 
preeminent growth potential. It has also been described by Carlson et al. (2008), that with a 
long period of time of incubation, the uppermost layers of the epithelium began to be thicker, 
being the suggested period of time of incubation for 7 to 14 days. 
Another notable factor that changes the quality of the 3D skin equivalents is the type of collagen 
that is used to fabricate the matrix, as with some of the collagen batches, a non-jellified matrix 
was obtained after the period of incubations in our protocol. To avoid this trouble, Carlson et 
al. (2008) suggest keeping on ice all the compounds needed for the construction of the collagen 
matrix until the gel mixture is placed onto the insert. On this way, the collagen should not 
prematurely precipitate.  
In future evaluation of 3D skin equivalents, further differentiation markers of the skin, such as 
involucrin and other cytokeratins, in untreated and treated skin models should be studied. Well-
developed stratum corneum can be confirmed by scanning electron microscopy. Also, markers 
that are known to induce or decrease TGase1 expression could be important in this study. 
Moreover, different doses of the TGase1/NG complex, longer treatment, potential effects of 
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the complex in immune responses and toxicity tests would help to understand disease and 
therapy mechanisms. To achieve this, Haneda et al. (2016), for example, analysed gene 
expression of wildtype and TGM1 -/- epidermis using microarrays to observe genes involved 
in innate immune system such as some cytokines or G-CSF, but cytokines and chemokines can 
also be analysed by ELISA. Cellular viability of 2D and 3D cultured keratinocytes and 
cytotoxicity can be assessed by MTT. Flow cytometry can be used to study the extent of 
apoptosis and necrosis in response to the nanocarrier. Also, to test dermal toxicity in 3D skin 
equivalents protocols like the one described by Jung et al. (2014) could be tested. To test skin 
irritation, Jung et al. (2014) unpacked the tissues on delivery and transferred them into 6 well 
plates with culture medium to expose the tissues to the chemicals. D-PBS and SDS were used 
as negative and positive control, respectively. After incubation with the test materials, tissues 
were treated with MTT. Afterwards, Formazan extraction was carried out before optical density 
was measured (Jung et al., 2014). Finally, to evaluate DNA lesions, an alkaline single-cell gel 
electrophoresis can be assessed. 
In addition, as we did with the studies of RNA level in keratinocytes grown in a 2D monolayer, 
we wanted to compare human skin models with skin models built by porcine keratinocytes and 
fibroblasts. Pig skin has been used in previous studies as models for wound healing, 
transdermal penetration and delivery, radiation and UV effects, and dermal toxicology (Abd et 
al., 2016). However, no literature concerning 3D skin equivalents from porcine skin samples 
have been found.  
To accomplish this, we obtained tissue samples from a Spanish abattoir for the isolation of skin 
cells. The first samples that we obtained were old, and even if we isolated them and left in 
culture for 14 days, no cells grew. More skin samples were acquired from the same 
slaughterhouse, and after isolation, only keratinocytes grew in culture. Afterwards, more 
samples were received, but all them arrived contaminated. We hypothesized that this was due 
to shipment conditions. Despite precautions were taken to keep the samples between 2 and 8oC, 
as instructed by manufacturer guidelines, the exceptional and unforeseeable high temperatures 
affected the medium temperature raising it over the recommended storage temperature. We 
proceed with the extraction of the skin cells, as we needed fibroblasts to perform the skin 
models on the same way we constructed the human skin equivalents, but no fibroblasts grew, 
so we could not build the 3D skin models from pig samples.  
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One of the issues were the contaminations obtained when extracting skin cells (keratinocytes 
and fibroblasts). Apart from the high temperatures during the transport of the samples, this 
could be also explained by the fact that skin biopsy conditions were not done in sterile 
conditions like in humans (in a surgery room with sterile instruments). Before the animal was 
slaughtered, a skin sample was biopsied with non-sterile instruments and in a non-sterile room. 
Sample was not disinfected until it was delivered in the laboratory. Other explanation to the 
contaminations can be our protocol for extracting skin cells. We adapted our protocol for the 
isolation of fibroblasts and keratinocytes from human skin biopsies to the protocols suggested 
by Hengge et al. (1996) and Ponce et al. (2017) for the extraction of porcine skin cells.  
In further studies, we will keep looking for local abattoirs that will be willing to provide us skin 
samples to avoid the long transport and reduce the risk of contamination. If the difficulties in 
finding local abattoirs will persist, an optimization of the transport condition, such as special 
packaging will be needed. Also, if samples from Spain are still been delivered, the protocol for 
the isolation of fibroblasts and keratinocytes should be also optimized. Thanks to the 
aforementioned modification in sourcing the skin simples and in the protocols, we expect the 
successfully extraction of skin cells from pigs, in order to develop equivalents 3D skin models. 
This would allow us to widen the knowledges of porcine skin and at the same time it will help 
us to overcome the difficulties in getting human skin simples, giving us the opportunity to 
better comprehend protein substitution, specifically of our TGase1/NG complex and its 
delivery in the epidermis, and to the development of new treatments for skin diseases.   
 
5.4. TGase1/NG COMPLEX ENTERS THE KERATINOCYTES 
We have seen that TGM1 is expressed in our cells on RNA level, and that the TGase1/NG 
complex used to treat the 3D skin equivalents penetrates into the epidermis.  
To assess the specific location of the recombinant protein TGase1 and the nanogel, which is 
the main goal of the project, keratinocytes isolated from human control biopsies, and from 
porcine control skin samples, were cultured in a 2D monolayer on top of coverslips. When cells 
were about 70% confluent, cells were treated with the 2% labelled TGase1 (Alexa Fluor® 
488)/NG (Rhodamin) complex (50 μg nanogel loaded with 1 μg TGase1) either for 3 hours or 
24 hours. After incubation times, cells were either stained with LysoTracker Deep Red for 
posterior fixation, as LysoTracker Deep Red is a fluorescent dye which application has to be 
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performed in live cells, or directly fixated with ice-cold methanol for immunohistochemistry. 
After a succession of washes, permeabilization, and blocking, cells were incubated with the 
primary antibody (anti GM130, anti E-cadherin or anti EEA1). Anti GM130 is a specific 
marker for Golgi, anti E-cadherin tracks the membrane, anti EEA1 detects the endoplasmic 
reticulum, and LysoTracker Deep Red shows the lysosomes. After incubation overnight, cells 
were incubated with the secondary antibody (Alexa Fluor® 633) and counterstained with DAPI 
(to stain the nuclei) for the visualisation under the confocal microscope. 
The confocal fluorescence microscope can remove blur from outside of the focal plane of the 
image (Jonkman and Brown, 2015). Confocal microscopy is an optimal imaging technique that 
scans a focused point of light around a sample to reconstruct an image in a point-by-point 
manner. For the detection, a pinhole is used, increasing the resolution and contrast compared 
to wide field illumination. Researchers have used the different confocal microscopies for skin 
imaging (Calzavara-Pinton et al., 2008; Gareau, 2011; Rodríguez‐Leyva et al., 2014). 
Rodríguez‐Leyva et al. (2014), for example, analysed keratinocytes from skin samples with a 
confocal laser scanning microscope. 
We analysed our samples with a Zeiss LSM 800, a confocal laser scanning microscope, 
observing that TGase1, as well as the nanogel, enters the keratinocytes (Figure 18-25). When 
human and pig cells were stained with anti E-cadherin, anti EEA1, anti GM130, and 
LysoTracker Deep Red die (Figure 18 and 22, 19 and 23, 20 and 24, and 21 and 25, 
respectively), TGase1 and nanogel seem to be associated to the membrane, but also to be in the 
cytoplasm, in each of those organelles. This could be due to the fact that TGase1 is also present 
in proliferating cells and in intact or proteolytically processed cytosolic or membrane-anchored 
forms. For this reason, our findings suggest that TGase1 and nanogel are present in cytosol, as 
well as in plasma membrane.  
Steinert et al. (1996) showed that the location of TGase1 in cytosol or in membrane is 
influenced by myristate and palmitate modifications. During TGase1 synthesis, it is N-
myristoylated, and in proliferating or differentiating cells, it is modified. Candi et al. (1998) 
suggested that TGase1 is an enzyme presented also as both forms, cytosolic and membrane-
bound. In addition, TGase1 is involved in the catalysing of lysine crosslinking of precursor 
proteins during the formation of the cytoplasmic layer of the cornified cell envelope (Herman 
et al., 2009). Therefore, our results seem to corroborate the location of TGase1 in cytosol and 
in membrane.  
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The fluorescent signal of rhodamine appears always to be stronger that Alexa Fluor® 488 
signal, which is due to a 2% TGase solution in the nanogel. 
When the human keratinocytes were treated for 3 hours, TGase1/NG complex seems to be 
located around the nuclei, in the cytoplasm, and associated to membrane, as well as when cells 
were treated for 24 hours. Same results are shown for pig keratinocytes. Also, we can see that 
the TGase1 has a different distribution pattern through the cells when comparing to the nanogel, 
which means that the TGase1 is released from the nanogel PNIPAM-dPG.  
In addition, senescent cell appearance was shown mainly in human primary keratinocytes after 
24 hours of the treatment. This suggests that treatment could be causing senescence on the 
cells. However, nearly no senescence was shown in pig primary keratinocytes, therefore the 
senescent cell appearance could be also due to the age of the cells, as human primary 
keratinocytes were relatively older than the pig keratinocytes. Despite these differences, 
replicates of the experiment with cells of the same passage and more time points should be 
carried out to finally understand the treatment.  
Atypical distribution of some antibodies such as lysotracker and anti E-cadherin were observed 
for both human and pig primary keratinocytes. This can be due to a wrong concentration of the 
reagents used. Other antibodies and concentrations should be used in future experiments to 
replicate these data and analyse them for a better comprehensension of the cellular location of 
the TGase1 and nanogel. 
To avoid senescence in future experiments, cells can be treated with the TGase1/NG when they 
are about 50% confluent. Also, different concentrations and time points of the protein and the 
nanogel could be used to compare the effect of the treatment on the cells when more or less 
protein is added. Furthermore, optimisation of the antibody concentrations would be an 
important step to further understand the TGase1/NG location in the cells.   
Gerecke et al. (2017) carried out studies with the PNIPAM-dPG for 3 hours, 24 hours, and 48 
hours incubation times showing intracellular localization in keratinocytes, corroborating our 
findings. Also, their stains, and ours using LysoTracker Deep Red, indicated strong 
colocalization of the nanogel with lysosomal compartments when cells are exposed to a long 
incubation times, which was mentioned too by Iversen, Skotland and Sandvig in 2011. This 
reveals that the final or major part of the intracellular fate of the nanogels in HaCaT cells and 
keratinocytes are the lysosomes. Rancan et al. (2017) carried out studies with intact and 
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disrupted skin barrier, indicating that the nanogel is capable of penetrating to deeper layers of 
the stratum corneum, and also in the viable epidermis and dermis when the skin barrier was 
disrupted. They also showed that the nanogel enters the keratinocytes and HaCaT cells, 
therefore in line with other studies mentioned.  
Because TGase1 has been shown to be membrane-associated and expressed in the epidermis, 
specifically in the granular layer (Kim et al. 1995; Jeon, Dijan and Green, 1998), Aufenvenne 
et al. (2013) developed sterically stabilized liposomes with encapsulated recombinant human 
TGase1, equipped with a highly cationic lipopeptide, showing the delivery of the TGase1 in 
the keratinocyte’s plasma membrane as a causative therapy for ARCI. However, liposomes can 
be unstable under environmental stress, while PNIPAm is soluble at room temperature but its 
phase separates at body temperature (Calderon et al., 2010; Cuggino et al., 2011).  
To further evaluate tracking of TGase1 and PNIPAM-dPG nanogel, transmission electron 
microscopy can be used. In this microscopy technique a beam of electrons is transmitted 
through a specimen to form an image. For that, immunogold labelling and stainings can be 
carried out and images can be compared to the ones obtained with confocal microscopy. Also, 
other microscopy technique is atomic force microscopy, a very-high-resolution type of 
scanning probe microscopy that provide images of atoms on or in surfaces.  
In addition, other markers can be evaluated in pig and human keratinocytes, to keep comparing 
them, as there is not so much literature concerning them. Protein expression and location could 
be analysed by flow cytometry. Also, the study of all these markers with keratinocytes isolated 
from ARCI-patients would allow us to understand the fate of the PNIPAM-dPG nanogel and 
TGase1.  
 
5.5. PIG SKIN EXPLANTS 
Because small skin samples can be propagated in culture with the advantage of that all type of 
cells from the skin are present in the skin explant (Mathes, Ruffner and Graf-Hausner, 2014), 
we planned on carrying out studies to test our therapeutic TGase1 in ex vivo conditions, in skin 
explants. Due to the obstacles for obtaining human skin samples, we opted for culturing porcine 
skin explants. We wanted to culture the skin explants for 13 days, the same period of time as 
3D skin equivalents were in culture and compare untreated and treated skin explants by 
harvesting and posterior immunohistochemistry and immunocytochemistry. Skin explants 
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were going to be treated with 2% of labelled TGase1/NG, the same concentration used for the 
skin models. Pig skin explants were first cultured for 13 days, with no TGase1/NG treatment, 
but no signals of skin explant growing were observed. Some changes were expected, for 
example observable modifications in the colour medium when the culture medium was not 
changed for a couple of days, which means that explants need more nutrients; therefore a 
medium change, as literature for human skin equivalents suggest changing medium every other 
day (Varani et al., 2007). This was due to the fact that samples were old, and/or they were 
treated and processed before slaughtering.  
In consequence, obtaining skin samples became a challenge influencing our research as 
previously mentioned.  
In future studies, other sources and optimization of the transport conditions will be evaluated. 
In addition, with skin explants in culture, paraffined sections from human or porcine skin 
explants can be stained with HE to evaluate the morphology, followed by qualitative analysis, 
and compare it with the 3D skin equivalents constructed. Immunohistochemistry experiments 
with TGase1, keratins, and other markers involved in differentiation should be tested. With 
human and porcine explants, we can also evaluate the depth of penetration of the TGase1/NG 
complex. Characterising skin explants will give us a more accurate knowledge of the therapy.  
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6. CONCLUSION 
ARCI is a rare and severe skin disease marked by genetic heterogenicity, and with no causative 
treatments available, making a targeted therapy extremely necessary.  
Different expression markers involved in ARCI were analysed in keratinocytes isolated from 
human controls and ARCI-patients with mutation in TGM1, and keratinocytes extracted from 
porcine skin samples on RNA level. After observing expression of TGM1 on RNA level for all 
samples, we constructed three-dimensional skin models to successfully characterize control 
and TGM1 patient 3D skin models using haematoxylin and eosin stainings, and 
immunohistochemical stainings. We also tested the fate of PNIPAM-dPG, a thermosensitive 
nanocarrier optimal for delivering proteins in the epidermis, developed by our group. This 
nanocarrier was labelled together with TGase1 for the detection of its delivery in the skin.  
After confirmation of the delivery of TGase1 in the skin, we confirmed using confocal 
microscopy that TGase1, as well as the nanogel, enters the keratinocytes. After 3 hours and 24 
hours treatment, the complex is located around the nuclei, therefore not toxicity should be 
detected, in the cytoplasm and in the plasma membrane for both porcine and human 
keratinocytes.  
To summarize, we provide new results not previously shown in the literature to contribute the 
overall goal of developing therapeutic approaches using protein replacement. We therefore 
corroborate the expression of differentiation markers involved in ARCI in human differentiated 
keratinocytes and in treated and untreated ARCI-patient cells, and we propose some results 
concerning the expression of those genes in pig differentiated keratinocytes. In addition, we 
present some analysis concerning the expression of some keratins and TGase1 in developed 
3D skin models from control samples. Furthermore, we add new data indicating the organelle 
location of TGase1 and PNIPAM-dPG nanocarrier in keratinocytes derived from human and 
porcine control skin samples, contributing to the main objective of this project. And finally, it 
has to be mentioned the not achievement of ex vivo data due to already mentioned issues.  
However, further studies to confirm this and to establish the protein substitution for ARCI 
patients are important steps to be taken in consideration. Examples of these studies are the 
evaluation of differentiation markers of the skin in untreated and treated healthy and diseased 
primary keratinocytes grown in a 2D monolayer, in control and diseased skin models, and in 
skin explants. Different doses and longer treatment should also be tested to determine optimal 
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delivery conditions. It is also important to analyse the depth of penetration of the TGase1/NG 
complex, and its possible toxic effects through toxicity experiments such as MTT assay or flow 
cytometry to study apoptosis. Specifically, to study the depth of penetration, obtaining skin 
explants would be very important, as it would provide us more accurate results. Finally, we 
would also like to look at the potential effects of the therapeutic complex in immune responses, 
as it has been seen in previous studies (Haneda et al., 2016) that in TGM1 -/- epidermis the 
expression of genes involved in innate immune system is increased. This can be assess using 
microarrays. In addition, studies with different cell lines for both control and patient samples, 
and executing the experiments with replicates, would be very important points to be taken in 
consideration. Different microscopy techniques such as Atomic force microscopy, 
transmission electron microscopy, and confocal microscopy will be also used to track the 
therapeutic protein TGase1 and the nanocarrier.  
The work presented in this thesis provides a better comprehension of a possible new protein 
replacement therapy for ARCI patients with TGM1 mutations, as we provide new results 
concerning the tracking of the delivery of the TGase1/PNIPAM-dPG complex. Furthermore, 
this strategy could be used to develop further therapeutic approaches for other proteins that are 
defective in other cases of ARCI or even other monogenic skin diseases.  
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